Therapeutic regimens and methods for lowering blood glucose and / or weight using GLP-1R and GCGR balancing agonists - Patent Application 20070229633

JP2024500324A5Inactive Publication Date: 2024-11-20SPITFIRE PHARMA LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534386
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-28
Filing Date
2021-12-07
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for obesity and diabetes, particularly non-alcoholic steatohepatitis (NASH), lack effective and safe pharmacological options for weight loss, with existing GLP-1RA therapies associated with gastrointestinal side effects and suboptimal weight loss outcomes, and dual GLP-1R/GCGR agonists requiring improved dosing regimens.

Method used

Development of dual GLP-1R/GCGR agonist peptides with balanced affinity for both receptors, formulated to reduce adverse events such as nausea and diarrhea, and administered weekly to induce significant weight loss and improve metabolic parameters.

Benefits of technology

The dual agonist peptides achieve at least 5-10% weight loss in 12 weeks with reduced gastrointestinal side effects, significantly improving liver fat content and metabolic markers, and show promise in treating conditions like NASH and PCOS.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to weekly dosing regimens, formulations and methods of use of dual GLP-1R and GCGR agonists, including but not limited to the dual agonist peptide product of SEQ ID NO:1, for the treatment of chronic weight control, obesity, and / or glycemic control.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority to U.S. Provisional Patent Application No. 63 / 122,117, filed December 7, 2020, U.S. Provisional Patent Application No. 63 / 211,157, filed June 16, 2021, and U.S. Provisional Patent Application No. 63 / 249,468, filed September 28, 2021, each of which is incorporated by reference in its entirety into this application.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on December 7, 2021, is named MED008PCT_ST25.TXT and is 8453 bytes in size.

[0003] Technical Field The present disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of use thereof. [Background technology]

[0004] The increasing prevalence of obesity, diabetes, nonalcoholic fatty liver disease (NAFLD) and its advanced form, nonalcoholic steatohepatitis (NASH), is a multi-emerging global health crisis that is a major cause of patient morbidity and mortality, as well as a major economic burden. Obesity is a key risk factor for type 2 diabetes and NASH, and approximately 90% of patients with type 2 diabetes are overweight or obese. Obesity is a rapidly growing problem worldwide, with more than 65% of adults in the United States currently overweight (Hedley, AA et al. (2004) JAMA 291: 2847-2850). NASH is expected to become the leading cause of liver transplants in the near future. There is a need for the development of safe and effective pharmaceutical treatments for obesity and diabetes. The present disclosure provides improved peptide drugs for the treatment of disorders associated with obesity or / and diabetes, such as nonalcoholic steatohepatitis (NASH) and polycystic ovarian syndrome (PCOS).

[0005] In the United States (US), NASH is the leading cause of end-stage liver disease or liver transplants. Obesity is the leading cause of NASH, and weight loss results in reduced liver fat and amelioration of NASH. More than 80% of individuals with NASH are overweight or obese, and since there are currently no US Food and Drug Administration (FDA)-approved pharmacological options available to induce weight loss, the majority of treatments are based on lifestyle interventions to achieve weight loss. However, it is difficult to achieve and maintain long-term weight loss with lifestyle modifications alone.

[0006] Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with modest weight loss at approved doses, and these agents have emerged as treatment options for patients with NASH. In a recent clinical trial, liraglutide, a once-daily GLP-1RA, was associated with resolution of NASH and showed a trend toward improved liver fibrosis. However, patients only lost 5.5% of their body weight. In one study, weight loss of 10% or more was required for optimal NASH resolution. Higher levels of weight loss are also associated with reduced incidence of cardiovascular disease and non-hepatic malignancies, which represent the most serious complications faced by patients with NASH.

[0007] GLP-1RA exerts a central effect on appetite and feeding, while GCR agonist increases energy expenditure in animal models and humans.The action of GCR agonist and GLP-1RA has been shown to synergistically promote weight loss compared to GLP-1RA alone.GCR also enhances lipolysis and inhibits the synthesis of hepatic fat, which provides an additional pathway for the reduction of hepatic fat and the disappearance of NASH.

[0008] Dual agonists combine GCR with GLP-1RA in the same molecule. In obese non-human primates, chronic administration of GLP-1R / GCR dual agonists reduced body weight and improved glucose tolerance to a greater extent compared with GLP-1RA monoagonists. Clinical trials of cotadutide, a GLP-1 / GCR dual agonist with a 5:1 bias of GLP-1 to glucagon activity, demonstrated a significant 39% reduction in liver fat content in just 6 weeks and a greater improvement in NASH-associated alanine aminotransferase (ALT) reduction than liraglutide alone. However, the extent of weight loss with cotadutide treatment over 26 weeks was comparable to liraglutide (5.4% vs. 5.5%), suggesting that the 5:1 ratio, while acceptable for liver fat reduction, is not optimal for weight loss. Balanced (1:1) agonism has been shown to be associated with greater weight loss and metabolic effects than biased ratios that favor one agonist over the other. A recent study with the balanced dual agonist JNJ 64565111 showed surprising results, with an 8% reduction in body weight in just 12 weeks (NCT03586830).

[0009] Unfortunately, GLP-1RA is associated with high rates of nausea, vomiting and diarrhea. These drugs also need to be titrated over a long period of time to reduce side effects, and drugs with improved tolerability and administration regimes are needed.Therefore, there is still a need for suitable dosing (e.g., weekly instead of daily) with therapeutic doses to control blood glucose and / or induce weight loss, without gastrointestinal side effects and without the need to titrate to therapeutic levels. Summary of the Invention The problem the problem is trying to solve

[0010] Described herein are dual agonist peptides and their products (e.g., formulations) and their uses for treating disorders associated with the function of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR), including, but not limited to, insulin resistance or / and obesity, e.g., type 2 diabetes, metabolic syndrome, cardiovascular disease (including coronary artery disease such as atherosclerosis and myocardial infarction), hypertension, NASH, chronic kidney disease, chronic weight management, and PCOS, as well as their uses in treating conditions associated with such disorders. Such dual agonist peptides have affinity for both GLP-1R and GCGR, which can be determined, for example, by the cellular assays described herein or using another assay for making such determinations. In some embodiments, the dual agonist peptide is any one of SEQ ID NOs: 1-10, or derivatives thereof, e.g., conservatively substituted derivatives thereof, and / or combinations thereof. In some embodiments, the dual agonist peptide exhibits approximately equal affinity for GLP-1R and GCGR, which can be determined using the cellular assay described above, and in a preferred embodiment is SEQ ID NO:1, or a derivative thereof. [Means for solving the problem]

[0011] In some embodiments, the present disclosure provides pharmaceutical dosage formulations of such dual agonist peptide(s) configured to control glycemia with reduced one or more adverse events compared to agonists with disproportionate affinity for GLP-1R and GCGR (e.g., semaglutide) or with excessively high maximum concentration (Cmax). In some embodiments, the present disclosure provides pharmaceutical dosage formulations of such dual agonist peptide(s) configured to induce weight loss for chronic weight management with reduced one or more adverse events compared to agonists with disproportionate affinity for GLP-1R and GCGR. The adverse events, in some embodiments, are selected from nausea, vomiting, diarrhea, abdominal pain and constipation upon administration to a mammal. These adverse events are typically observed following administration of (dual) agonists with rapid entry into the circulation, resulting in an excessively high Cmax. In some embodiments, administration of the dual agonist peptide(s) disclosed herein (e.g., SEQ ID NOs: 1-10 or derivatives thereof) may result in improved other outcomes (e.g., weight loss, fat loss, lipid profile) and / or pharmacokinetic (PK) parameters compared to agonists with disproportionate affinity for GLP-1R and GCGR (e.g., semaglutide).

[0012] In a preferred embodiment, the disclosure provides a method of lowering blood glucose and / or lowering body weight in a human, comprising administering to the human a pharmaceutical dosage formulation comprising SEQ ID NO:1, wherein the occurrence of one or more adverse events is reduced compared to an agonist having disproportionate affinity for GLP-1R and GCGR, the adverse events being selected from nausea, vomiting, diarrhea, abdominal pain and constipation upon administration to the human.

[0013] In certain embodiments, the present disclosure provides pharmaceutical dosage formulations of such dual agonist peptide(s) configured for the treatment of chronic weight management. In embodiments, a body mass index (BMI) of at least 25 (kg / m 2The present invention provides a treatment for chronic weight management in a human having a deficiency in schizophrenia by inducing weight loss in the human, the method comprising administering to the human once a week a pharmaceutical dosage formulation comprising a therapeutically effective amount of SEQ ID NO:1, wherein the human's weight is reduced by at least 5% (preferably at least about 5% to about 10%) from baseline at week 12.

[0014] Other aspects of the present disclosure are also contemplated, as would be understood by one of ordinary skill in the art. [Brief description of the drawings]

[0015] [Figure 1] 1 illustrates the results of weight loss following administration of ALT-801 (also referred to herein as pemviduetide) at doses of 1.2 mg and 1.8 mg compared to placebo measured over a 43 day period (see also Table 7). [Diagram 2] We describe the results of weight loss following weekly administration of ALT-801 (pembiduteide) after 6 and 12 weeks of treatment across different dose groups (1.2 mg, 1.8 mg, and 2.4 mg) versus a placebo group. [Diagram 3] Individual subject weight loss results following weekly dosing of ALT-801 vs. placebo at 1.8 mg for 12 weeks are described. [Figure 4] Individual subject weight loss results following weekly administration of ALT-801 vs. placebo at 2.4 mg for 12 weeks are described. [Diagram 5] 5A and 5B illustrate the absence of correlation between weight loss and age or BMI (body mass index), respectively. [Figure 6] Depicts pre-treatment vs. post-treatment (ALT-801 at 1.2, 1.8, or 2.4 mg) liver fat levels in all measurable subjects, where the first bar is the measurement at screening (baseline) and the second bar is the measurement at week 6. [Figure 7]The absolute change in liver fat levels after 6 weeks of treatment with ALT-801 (treatment at 1.2, 1.8 or 2.4 mg) in all measurable subjects compared to placebo is described. [Figure 8] FIG. 1 illustrates the relative change in liver fat levels after 6 weeks of treatment with ALT-801 (treatment at 1.2, 1.8 or 2.4 mg) compared to placebo in all measurable subjects. [Figure 9] To describe the absolute change in liver fat levels after 6 weeks of treatment with ALT-801 (treatment at 1.8 or 2.4 mg) compared to placebo in all steatotic subjects [Figure 10] To describe the relative change in liver fat levels after 6 weeks of treatment with ALT-801 (treatment at 1.8 or 2.4 mg) compared to placebo in all steatotic subjects [Figure 11] A greater than 90% reduction in liver fat to undetectable levels by MRI-PDFF (magnetic resonance imaging proton density fat fraction) after 6 weeks of treatment with ALT-801 (doses of 1.8 and 2.4 mg), where each subject had a baseline liver fat content of 19.5%, 17% and 12.5%, respectively. Weekly treatment with doses of 1.8 mg or 2.4 mg of ALT-801 reduced liver fat content (LFC) to undetectable levels (below LOD (limit of detection)). [Figure 12] FIG. 1 illustrates the improvement of blood pressure as a biomarker of cardiovascular risk in all groups after 12 weeks of treatment with ALT-801 (doses 1.2, 1.8 and 2.4 mg) compared to placebo, where the first bar is systolic pressure and the second bar is diastolic pressure in each group. Weekly treatment with ALT-801 improved blood pressure across all dose groups (1.2 mg, 1.8 mg or 2.4 mg). [Figure 13]Describe improvements in serum lipid levels as biomarkers of cardiovascular risk (total cholesterol ("Tot. Chol."), high density lipoprotein ("HDL Chol."), low density lipoprotein ("LDL Chol."), and triglycerides) across all dose groups (doses of 1.2, 1.8 and 2.4 mg) compared to placebo after 12 weeks of treatment. [Figure 14] Figure 1 shows BMI (body mass index) measured at baseline (screening) and after 12 weeks (day 85) of treatment with ALT-801 at weekly doses of 1.2 mg, 1.8 mg, and 2.4 mg compared to placebo. All treatment groups reduced BMI, with the 1.8 mg and 2.4 mg dose treatment groups showing significant reductions compared to placebo. [Figure 15] Figure 1 shows early satiety and appetite suppression measured after 12 weeks of treatment with ALT-801 at weekly doses of 1.2 mg, 1.8 mg, and 2.4 mg compared to placebo. All treatment groups showed anorexia and a dose response. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present disclosure relates to dual agonist peptide(s), as well as pharmaceutical dosage formulations comprising the same, and methods of using the same. The dual agonist peptide has an affinity for the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), in preferred embodiments, approximately equal affinity for the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), which can be determined using a cellular assay. In some embodiments, the present disclosure provides pharmaceutical dosage formulations configured to control blood glucose. In some embodiments, blood glucose is better controlled (e.g., lowered and stabilized) after administration of the dual agonist peptide compared to selective (e.g., semaglutide) and / or unbalanced agonists. In some embodiments, the present disclosure provides pharmaceutical dosage formulations configured to induce weight loss, including for the treatment of chronic weight management. In some embodiments, weight loss is improved (e.g., reduced and stabilized) after administration of the dual agonist peptide compared to selective (e.g., semaglutide) and / or disproportionate agonists. In some embodiments, such pharmaceutical dosage formulations show reduced adverse events compared to agonists with selective (e.g., semaglutide) and / or disproportionate affinity for GLP-1R and GCGR. In some embodiments, adverse events may include nausea, vomiting, diarrhea, abdominal pain and / or constipation typically observed after or upon administration of agonists with disproportionate affinity for GLP-1R and GCGR (e.g., semaglutide) to mammals. In some embodiments, the present disclosure provides novel peptide-based dual GLP-1 / glucagon receptor agonists designed to treat the underlying metabolic dysfunction that leads to nonalcoholic steatohepatitis (NASH).

[0017] In some embodiments, the dual agonist peptide is any one of SEQ ID NOs: 1-10, or derivatives thereof. In preferred embodiments, the dual agonist peptide is EU-A1873 (SEQ ID NO: 1), EU-A1588 (SEQ ID NO: 2), EU-A1871 (SEQ ID NO: 3), or EU-A1872 (SEQ ID NO: 4) as shown in Table 1.

[0018] [Table 1] In Table 1, the numbers 1, 5, 10, 15, 20, 25 and 30 at the top refer to the amino acid residue numbers (a total of 29 amino acid residues are present in each of SEQ ID NOs: 1 to 5). Semaglutide shown in Table 1 is SEQ ID NO: 11 (31 amino acid residues). As shown in Table 1, SEQ ID NO: 1 (EU-A1873 in Table 1; also known as ALT-801 or pemviduetide) has the following amino acid sequence: 1 His- 2 Aib- 3 Gln- 4 Gly- 5 Thr- 6 Phe- 7 Thr- 8 Ser- 9 Asp- 10 Tyr- 11 Ser- 12 Lys- 13 Tyr- 14 Leu- 15 Asp- 16 Glu*- 17 Lys # - 18 Ala- 19 Ala- 20 Lys*- 21 Glu- 22 Phe- 23 Ile- 24 Gln- 25 Trp- 26 Leu- 27 Leu- 28 Gln- 29 Thr-NH2, (In the formula, *indicates that the lactam bridge is formed between Glu16 and Lys20, and 17Lys# indicates that the glucuronic acid C-18 * (EuPort G, Z17CO2H). In other words, SEQ ID NO: 1 represents the binding site of 17 29 amino acid residues and glucuronic acid / C linked to Lys 18 A peptide amide consisting of a diacid moiety, wherein 16 Glu and 20 The side chains of Lys form the following intramolecular cycle:

[0019] [ka]

[0020] In some embodiments, the dual agonist peptide comprises: 1) His Xaa1 Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Xaa2 Ala Ala Lys Glu Phe Ile Gln Trp Leu Gln Thr (SEQ ID NO: 6) 20 25 wherein Xaa1 is any amino acid, preferably Aib (α-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine)); Xaa2 is Lys (N-omega(1-(17-carboxyl-heptadecyloxy)beta-D-glucuronyl)), or Lys(Z17CO2H) (wherein Z17CO2H is (beta-D-glucuron-1-yl)-1-oxa)17-carboxyheptadecane); Glu16 and Lys20 are cyclized together via their respective side chains to form a lactam bond; or a derivative thereof; 2) His Xaa1 Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Xaa2 Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr (SEQ ID NO: 7) 20 25 wherein Xaa1 is any amino acid, preferably Aib (α-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine)); Xaa2 is Lys(Me17CO2H) (wherein Me17CO2H is beta-D-merobiouranyl-1-yl)-1-oxa)17-carboxyheptadecane); Glu16 and Lys20 are cyclized together via their respective side chains to form a lactam bond); or a derivative thereof; 3) His Xaa1 Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Xaa3 Trp Leu Leu Gln Thr (SEQ ID NO: 8) 20 25 wherein Xaa1 is any amino acid, preferably Aib (α-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine); Glu16 and Lys20 are cyclized together through their respective side chains to form a lactam bond; Xaa3 is Lys(Z15CO2H), wherein Z15CO2H is (beta-D-glucuron-1-yl)-1-oxa)15-carboxyheptadecane; or a derivative thereof; 4) His Xaa1 Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Glu 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Xaa4 Trp Leu Leu Gln Thr (SEQ ID NO: 9) 20 25 wherein Xaa1 is any amino acid, preferably Aib (α-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine); Glu16 and Lys20 are cyclized together through their respective side chains to form a lactam bond; Xaa4 is Lys(Z17CO2H) (wherein Z17CO2H is (beta-D-glucuron-1-yl)-1-oxa)17-carboxyheptadecane); or a derivative thereof; or 5) His Xaa1 Gln Gly Thr Phe Thr Ser Asp Tyr Ser Xaa5 Tyr Leu Asp Glu 1 5 10 15 Xaa2 Ala Ala Lys Glu Phe Ile Gln Trp Leu Leu Gln Thr (SEQ ID NO: 10) 20 25 wherein Xaa1 is any amino acid, preferably Aib (α-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine)); Xaa2 is Lys (N-omega(1-(17-carboxyl-heptadecyloxy)beta-D-glucuronyl)) or Lys(Z17CO2H) (wherein Z17CO2H is (beta-D-glucuron-1-yl)-1-oxa)17-carboxyheptadecane); Xaa5 is Arg, and Glu16 and Lys20 are cyclized together via their respective side chains to form a lactam bond); or a derivative thereof.

[0021] In a preferred embodiment, the dual agonist peptide has an amino acid sequence of any one of SEQ ID NOs: 1-10, or derivatives thereof. In a preferred embodiment, the dual agonist peptide is SEQ ID NO: 1. In an embodiment, provided herein is a pharmaceutical formulation of SEQ ID NO: 1 in an aqueous buffer solution, referred to herein as ALT-801. The dual agonist peptide products herein, including SEQ ID NO: 1, contain an amino acid side chain amide bond (lactam bridge), and a EuPort side chain consisting of glucuronic acid linked to a fatty acid side chain. The surfactant side chain consisting of a hydrophilic saccharide group covalently attached to the peptide via a linker amino acid, and a hydrophobic alkyl chain moiety, results in the formation of micelles after subcutaneous (SC) injection, which results in slower entry into the circulation. The slower entry is accompanied by a lower maximum concentration (Cmax), resulting in reduced GI side effects and better tolerability. This latter feature also enhances binding to plasma proteins, improves metabolic stability, and extends half-life (t1 / 2). The design of SEQ ID NO:1 was successful in obtaining a co-agonist with equivalent (1:1) activity at both receptors and 100% activity at approximately 40 pM.

[0022] The synthesis of dual agonist peptides (e.g., SEQ ID NOs: 1-10, or derivatives thereof) is described herein (e.g., Example 1) and in U.S. Patent No. 9,856,306 B2, the entirety of which is incorporated by reference into this disclosure. In some embodiments, the dual agonist peptides may include one or more conservatively substituted amino acids as described herein. In a preferred embodiment, SEQ ID NO: 1 may include one or more conservatively substituted amino acids, but preferably does not include one or more conservatively substituted amino acids at amino acid residues 16, 17, or 20. In a preferred embodiment, SEQ ID NO: 2 may include one or more conservatively substituted amino acids, but preferably does not include one or more conservatively substituted amino acids at amino acid residues 16, 17, or 20. In a preferred embodiment, SEQ ID NO: 3 may include one or more conservatively substituted amino acids, but preferably does not include one or more conservatively substituted amino acids at amino acid residues 16, 20, or 24. In preferred embodiments, SEQ ID NO:4 may contain one or more conservatively substituted amino acids, but preferably does not contain one or more conservatively substituted amino acids at amino acid residues 16, 20, or 24, and SEQ ID NO:5 may contain one or more conservatively substituted amino acids, but preferably does not contain one or more conservatively substituted amino acids at amino acid residues 12, 16, 17, or 20.

[0023] The peptides of SEQ ID NOs: 1-10 can be referred to collectively herein as "dual agonist peptides" (or individually as "dual agonist peptides"), as each is an agonist for the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR). In some embodiments, the peptides are dual agonists of GLP-1R and GCGR, which can be determined by cellular assays such as those described in Example 2 herein. Briefly, in some embodiments, cellular assays can be performed by measuring cAMP stimulation or arrestin activation in CHO cells in which human GLP-1R or GCGR is expressed (LeadHunter assay (DiscoveRx)). Since the dual agonist peptides of SEQ ID NOs: 1-10 bind very tightly (>99%) to serum albumin, which can skew the results (see, e.g., Example 2 herein), preferably such assays are performed in the presence of 0.1% ovalbumin, as compared to 0.1% bovine serum albumin (BSA), which can be typical. In some embodiments, as determined using such assays, the dual agonist peptides exhibit parental agonism for both GLP-1R and GCGR. The dual agonist peptide may have a compatibility with GLP-1R and GCGR, and in a preferred embodiment, may have an approximately equal affinity for GLP-1R and GCGR. "Approximately equal affinity" means that the dual agonist peptide has an affinity for GLP-1R or GCGR that is about 2-3 times or less, preferably 2 times or less, than the affinity for the other, which can be determined by such a cellular assay. For example, as shown in the examples of the present specification, the dual agonist peptide SEQ ID NO: 1 (EU-A1873) was surprisingly found to be a dual agonist peptide that has approximately equal affinity for GLP-1R and GCGR (e.g., an EC50 of about 39 pm for GLP-1R (115% intrinsic activity) and an EC50 of 44 pm for GCGR (115% intrinsic activity)).This is different from GLP-1 "specific" compounds, including semaglutide and exendin-4, which are strongly biased to GLP-1R or show affinity only to GLP-1R, or glucagon, which is a hormone that is strongly biased to GCGR and does not show high or nearly equal affinity to both GLP-1R and GCGR.Oxyntomodulin, a natural hormone, has agonistic effects at both GLP-1 and glucagon receptors, but this activity is not strong and unbalanced.Those skilled in the art will understand that affinity to GLP-1R and GCGR can be determined by methods and / or assays other than those described herein, and such methods and / or assays for determining affinity are contemplated herein (e.g., the determination of nearly equal affinity can be made by such other methods and / or assays).

[0024] In an embodiment, as used herein, "a dual agonist peptide having approximately equal affinity for the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR)" refers to a dual agonist peptide having an affinity for GLP-1R or GCGR that is about 2-fold or less than its affinity for the other, as can be determined by such cellular assays. In an embodiment, the binding affinity of the dual agonist peptide for one receptor compared to the other is 1.9, 1.8, 1.6, 1.5, 1.4, or 1.2-fold or less, as can be determined by known cellular assays. In an embodiment, as used herein, "an agonist having disproportionate affinity for GLP-1R and GCGR" refers to an agonist peptide having an affinity for GLP-1R or GCGR that is at least about 1.5-fold greater than its affinity for the other, as can be determined by known cellular assays. In embodiments, the binding affinity of agonists with disproportionate affinity for GLP-1R and GCGR is at least 1.6, 1.8, 2, 2.5, 3, 5, 7.5, 10, 20 fold or more, as can be determined by known cellular assays.

[0025] A "peptide" (e.g., a dual agonist peptide) typically comprises two or more naturally occurring and / or non-naturally occurring amino acid residues linked via peptide bonds. Such amino acids may include naturally occurring structural variants of natural amino acids, naturally occurring non-proteinogenic amino acids, or / and synthetic non-naturally occurring analogs. The terms "peptide" and "polypeptide" are used interchangeably herein. Peptides include short peptides (about 2-20 amino acids), medium length peptides (about 21-50 amino acids), and long peptides (also called "proteins", >about 50 amino acids). In some embodiments, the peptide product comprises a surfactant moiety stably covalently attached to a peptide of about 50, 40, or 30 or less amino acids. Synthetic peptides can be synthesized, for example, using an automated peptide synthesizer. Peptides can also be produced recombinantly in cells expressing a nucleic acid sequence encoding the peptide. Conventional notation is used herein to depict peptide sequences, with the left-hand end of the peptide sequence being the amino (N)-terminus and the right-hand end of the peptide sequence being the carboxyl (C)-terminus. Standard one-letter and three-letter abbreviations of common amino acids are used herein.Unless otherwise specified as D- or DL- or the amino acid is achiral, the abbreviations used in the amino acid sequences disclosed herein represent L-amino acids, although the corresponding D-isomers can generally be used at any position (e.g., to resist proteolytic degradation).Abbreviations for other amino acids used herein are: Aib=a-aminoisobutyric acid (or 2-methylalanine or Ca-methylalanine);Xaa: typically includes any amino acid specifically defined in the formula.Abbreviations for other amino acids that may be used as described herein are: Ac3c = 1-aminocyclopropane-1-carboxylic acid; Ac4c = 1-aminocyclobutane-1-carboxylic acid; Ac5c = 1-aminocyclopentane-1-carboxylic acid; Ac6c = 1-aminocyclohexane-1-carboxylic acid; Aib = alpha-aminoisobutyric acid (or 2-methylalanine or C alpha-methylalanine); Bip = 3-(biphenyl-4-yl)alanine; Bip2Et = 3-(2'-ethylbiphenyl-4-yl)alanine; Bip2EtMeO = 3-(2'-ethyl-4'-methoxybiphenyl-4-yl)alanine; Cit = citrulline; Deg = 2,2-diethylglycine; Dmt = (2,6-dimethyl)tyrosine; 2FPhe = (2-fluorophenyl)alanine; The 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) and Tic-Phe dipeptide moieties, comprising 2FMePhe or 2FaMePhe = Ca-methyl-(2-fluorophenyl)alanine; hArg = homoarginine; MeLys or aMeLys = Ca-methyllysine; MePhe or aMePhe = Ca-methylphenylalanine; MePro or aMePro = Ca-methylproline; Nall or Nal(l) = 3-(1-naphthyl)alanine; Nal2 or Nal(2) = 3-(2-naphthyl)alanine; Nle = norleucine; Om = ornithine; and Tmp = (2,4,6-trimethylphenyl)alanine, have a reduced amide bond between the residues (designated Tic-Ψ[CFl2-NFl]-Ψ-Phe) and have the following structure:

[0026] [ka] has.

[0027] Unless otherwise specifically indicated or the context indicates otherwise, the present disclosure encompasses any and all forms of dual agonist peptides that may be produced, whether they are produced synthetically (e.g., using a peptide synthesizer) or by a cell (e.g., by recombinant production). Such forms of dual agonist peptides may include one or more modifications that may be made during synthesis or cellular production of the peptide, such as one or more post-translational modifications, whether or not the one or more modifications are deliberate. A dual agonist peptide may have the same type of modification in two or more different locations, or / and may have two or more different types of modifications. Modifications that may be made during the course of synthesis or cellular production of the dual agonist peptide, including chemical and post-translational modifications, include, but are not limited to, glycosylation (e.g., N-linked glycosylation and O-linked glycosylation), lipidation, phosphorylation, sulfation, acetylation (e.g., acetylation of the N-terminus), amidation (e.g., amidation of the C-terminus), hydroxylation, methylation, intramolecular or intermolecular disulfide bond formation, lactam formation between two side chains, pyroglutamic acid formation, and ubiquitination. The dual agonist peptide can have one or more modifications at any location, such as the N-terminus, the C-terminus, one or more amino acid side chains, or the dual agonist peptide backbone, or any combination thereof. In some embodiments, the dual agonist peptide is acetylated at the N-terminus or / and has a carboxamide (-CONH2) group at the C-terminus, which can increase the stability of the dual agonist peptide.

[0028] Possible modifications of the dual agonist peptide also include the deletion of one or more amino acids, the addition / insertion of one or more natural or / and non-natural amino acids, or the substitution with one or more natural or / and non-natural amino acids, or any combination or all thereof. The substitutions can be conservative or non-conservative. Such modifications can be deliberate, such as through site-directed mutagenesis or in the chemical synthesis of the dual agonist peptide, or can be accidental, such as through mutations occurring in the host cell producing the dual agonist peptide, or through errors resulting from PCR amplification. The non-natural amino acid can have the same chemical structure as the corresponding natural amino acid, but with D-stereochemistry, or it can have a different chemical structure and D- or L-stereochemistry. The non-natural amino acid can be utilized, for example, to promote helix formation or / and increase the stability (e.g., to resist proteolytic degradation) of the dual agonist peptide. A dual agonist peptide having one or more modifications relative to a reference dual agonist peptide may be referred to as an "analog" or "variant" of the reference dual agonist peptide, as appropriate. An "analog" typically retains one or more essential properties of the reference dual agonist peptide (e.g., receptor binding, receptor or enzyme activation, receptor or enzyme inhibition, or other biological activity). A "variant" may or may not retain the biological activity of the reference dual agonist peptide, or / and may have a different biological activity. Such a variant preferably retains its ability to act as an agonist of GLP-1R and GCGR, and in more preferred embodiments, has approximately equal affinity for GLP-1R and GCGR. In some embodiments, an analog or variant of a reference peptide has a different amino acid sequence than the reference dual agonist peptide.

[0029] The term "conservative substitution" refers to the replacement of an amino acid in a dual agonist peptide with a functionally, structurally or chemically similar natural or non-natural amino acid. In certain embodiments, the following groups: 1) glycine (Gly / G), alanine (Ala / A); 2) isoleucine (Ile / I), leucine (Leu / L), methionine (Met / M), valine (Val / V); 3) phenylalanine (Phe / F), tyrosine (Tyr / Y), tryptophan (Trp / W); 4) serine (Ser / S), threonine (Thr / T), cysteine ​​(Cys / C); 5) asparagine (Asn / N), glutamine (Gln / Q); 6) aspartic acid (Asp / D), glutamic acid (Glu / E); and 7) arginine (Arg / R), lysine (Lys / K), histidine (His / H) each contain naturally occurring amino acids that are conservative substitutions for one another. In further embodiments, each of the following groups contains natural amino acids which are conservative substitutions for one another: 1) non-polar: Ala, Val, Leu, Ile, Met, Pro (proline / P), Phe, Trp; 2) hydrophobic: Val, Leu, Ile, Phe, Trp; 3) aliphatic: Ala, Val, Leu, Ile; 4) aromatic: Phe, Tyr, Trp, His; 5) uncharged polar or hydrophilic: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln, Tyr; 6) aliphatic hydroxyl or sulfhydryl containing: Ser, Thr, Cys; 7) amide containing: Asn, Gln; 8) acidic: Asp, Glu; 9) basic: Lys, Arg, His; and 10) small: Gly, Ala, Ser, Cys. In other embodiments, amino acids may be grouped as conservative substitutions as follows: 1) hydrophobic: Val, Leu, Ile, Met, Phe, Trp; 2) aromatic: Phe, Tyr, Trp, His; 3) naturally hydrophilic: Gly, Ala, Pro, Ser, Thr, Cys, Asn, Gln; 4) acidic: Asp, Glu; 5) basic: Lys, Arg, His; and 6) residues that affect backbone orientation: Pro.

[0030] Examples of unnatural or non-proteinogenic amino acids include alanine analogs (e.g., α-ethyl Gly [α-aminobutyric acid or Abu], α-n-propyl Gly [norvaline or Nva], α-tert-butyl Gly [Tbg], α-vinyl Gly [Vg or Vlg], α-allyl Gly [Alg], α-propargyl Gly [Prg], 3-cyclopropyl Ala [Cpa], and Aib), leucine analogs (e.g., nor-leucine, Nle), proline analogs (e.g., α-MePro), phenylalanine analogs (e.g., Phe(2-F), Phe(2-Me), Tmp, Bip, Bip(2'-Et-4'-OMe), Na1, Na12, Tic, α-MePh, e, α-MePhe(2-F) and α-MePhe(2-Me)), tyrosine analogs (e.g., Dmt and α-MeTyr), serine analogs (e.g., homoserine [isothreonine or hSer]), glutamine analogs (e.g., Cit), arginine analogs (e.g., hArg, N,N'-g-dialkyl-hArg), lysine analogs (e.g., homolysine [hLys], Orn and α-MeLys), α,α-disubstituted amino acids (e.g., Aib, α,α-diethylGly[Deg], α-cyclohexylAla[2-Cha], Ac3c, Ac4c, Ac5c and Ac6c), and other unnatural amino acids disclosed in A. Santoprete et al., Pept. Sci., 17:270-280 (2011). α,α-disubstituted amino acids may result in conformational restriction or / and a-helix stabilization. Reduction of the amide bond between two residues (e.g., in Tic-Ψ[CF12-NF1]-Ψ-Phe) may increase protease resistance and, for example, alter receptor binding. The present disclosure encompasses all pharma- ceutically acceptable salts of the dual agonist peptides, including those with a positive net charge, those with a negative net charge, and those with no net charge.

[0031] An "alkyl" group refers to an aliphatic hydrocarbon group. An alkyl group can be saturated or unsaturated and can be straight-chained (linear), branched, or cyclic. In some embodiments, an alkyl group is not cyclic. In some embodiments, an alkyl group contains 1-30, 6-30, 6-20, or 8-20 carbon atoms. A "substituted" alkyl group is substituted with one or more substituents. In some embodiments, the one or more substituents are independently selected from halogen, nitro, cyano, oxo, hydroxy, alkoxy, haloalkoxy, aryloxy, thiol, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, amino, alkylamino, dialkylamino, arylamino, alkoyl, carboxyl, carboxylate, ester, amide, carbonate, carbamate, urea, alkyl, haloalkyl, fluoroalkyl, aralkyl, alkyl chain containing acyl groups, heteroalkyl, heteroari-cyclic, aryl, alkoxyaryl, heteroaryl, hydrophobic natural compounds (e.g., steroids), and the like. In some embodiments, the alkyl group as a substituent is a straight-chain or branched C i-C6 alkyl. Non-limiting examples of lower alkyl groups include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including all isomeric forms such as n-butyl, isobutyl, sec-butyl and / er / -butyl), pentyl (including all isomeric forms such as n-pentyl), and hexyl (including all isomeric forms such as n-hexyl). In some embodiments, the alkyl group is attached to the Na-atom of a residue of a peptide (e.g., Tyr or Dmt). In certain embodiments, the N-alkyl group is a linear or branched C1-C10 alkyl, or an aryl-substituted alkyl such as benzyl, phenylethyl, etc. One or two alkyl groups can be attached to the Na atom of the N-terminal residue. In some embodiments, the alkyl group is a 1-alkyl group attached to the C1 position of a sugar (e.g., glucose) via a glycosidic bond (e.g., O-, S-, N-, or C-glycosidic bond). In some embodiments, such 1-alkyl groups are unsubstituted or substituted C1-C30, C6-C30, C6-C 20 or C8-C 20 In some embodiments, the alkyl group (e.g., 1-alkyl group) is an aryl, -OH, -OR 1 , -SH, -SR 1 , -NH2, -NHR 1 , -N(R 1 )2, oxo(=O), -C(=O)R 2 , carboxyl (-CO2H), carboxylate (-CO2-), -C(=O)OR 1 , -OC(=O)R 3 , -C(=O)N(R 1 )2, -NR 4 C(=O)R 3 , -OC(=O)OR 5 , -OC(=O)N(R 1 )2, -NR 4 C(=O)OR 5 , and -NR 4 C(=O)N(R 1 )2(wherein, R 1 is independently at each occurrence hydrogen, alkyl, or aryl, or R1 and the nitrogen atom to which they are attached together form a heterocyclic or heteroaryl ring; R 2 is independently at each occurrence alkyl, heterocyclic, aryl, or heteroaryl; R 3 is independently at each occurrence hydrogen, alkyl, heterocycle, aryl, or heteroaryl; R 4 is, independently at each occurrence, hydrogen or alkyl; R 5is independently at each occurrence alkyl or aryl). In some embodiments, the alkyl group (e.g., 1-alkyl group) is internally or / and terminally substituted with a carboxyl / carboxylate group, an aryl group, or an -O-aryl group. In certain embodiments, the alkyl group (e.g., 1-alkyl group) is substituted with a carboxyl or carboxylate group at the distal end of the alkyl group. In further embodiments, the alkyl group (e.g., 1-alkyl group) is substituted with an aryl group at the distal end of the alkyl group. In other embodiments, the alkyl group (e.g., 1-alkyl group) is substituted with an -O-aryl group at the distal end of the alkyl group. The terms "halogen", "halide" and "halo" refer to fluoride, chloride, bromide and iodide. The term "acyl" refers to -C(=O)R, where R is an aliphatic group that can be saturated or unsaturated and linear, branched or cyclic. In certain embodiments, R contains 1-20, 1-10, or 1-6 carbon atoms. The acyl group can be optionally substituted with one or more groups, such as halogen, oxo, hydroxyl, alkoxy, thiol, alkylthio, amino, alkylamino, dialkylamino, cycloalkyl, aryl, acyl, carboxyl, ester, amide, hydrophobic natural compounds (e.g., steroids), and the like. The terms "heterocycle" and "heterocycle" refer to a monocyclic non-aromatic group or a polycyclic group containing at least one non-aromatic ring, where at least one non-aromatic ring contains one or more heteroatoms, independently of O, N, and S. The non-aromatic ring containing one or more heteroatoms may be bonded to or fused to one or more saturated, partially unsaturated, or aromatic rings. In certain embodiments, the heterocycle or heterocyclic group has 3-15, or 3-12, or 3-10, or 3-8, or 3-6 ring atoms.Heterocycles or heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, azocanyl, oxiranyl, oxetanyl, tetrahydrofuranyl (oxolanyl), tetrahydropyranyl, oxepanyl, and oxocanyl. The term "aryl" refers to a monocyclic aromatic hydrocarbon group or a polycyclic group containing at least one aromatic hydrocarbon ring. In certain embodiments, the aryl group has 6 to 15, or 6 to 12, or 6 to 10 ring atoms. Aryl groups include, but are not limited to, phenyl, naphthalenyl (naphthyl), fluorenyl, azulenyl, anthryl, phenanthryl, biphenyl, and terphenyl. The aromatic hydrocarbon ring of the aryl group may be bonded to or fused to one or more saturated, partially unsaturated or aromatic rings, such as dihydronaphthyl, indenyl, indanyl and tetrahydronaphthyl (tetralinyl). The aryl group may be optionally substituted with one or more (e.g., two or three) substituents independently selected from halogen (including -F and -Cl), cyano, nitro, hydroxyl, alkoxy, thiol, alkylthio, alkylsulfoxide, alkylsulfone, amino, alkylamino, dialkylamino, alkyl, haloalkyl (including fluoroalkyl such as trifluoromethyl), acyl, carboxyl, ester, amide, and the like. The term "heteroaryl" refers to a monocyclic aromatic group or a polycyclic group containing at least one aromatic ring, where at least one aromatic ring contains one or more heteroatoms independently selected from O, N and S. The heteroaromatic ring may be attached to or fused to one or more saturated, partially unsaturated or aromatic rings, which may contain only carbon atoms or which may contain one or more heteroatoms. In certain embodiments, heteroaryl groups have 5 to 15, or 5 to 12, or 5 to 10 ring atoms.Monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl (thiophenyl), oxadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridonyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridazinoyl, and triazinyl. Examples of bicyclic heteroaryl groups include, but are not limited to, indolyl, benzothiazolyl, benzothiadiazolyl, benzoxazolyl, benzisoxazolyl, benzothienyl (benzothiophenyl), quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzotriazolyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, cinnolinyl, quinazolinyl, quinoxalinyl, indazolyl, naphthyridinyl, phthalazinyl, quinazolinyl, purinyl, pyrrolopyridinyl, furopyridinyl, thienopyridinyl, dihydroisoindolyl, and tetrahydroquinolinyl.

[0032] In some embodiments, for example, the dual agonist peptide can be conjugated with a sugar, such as in a pharma- ceutically acceptable composition or lyophilizate. Sugars include monosaccharides, disaccharides, and oligosaccharides (e.g., trisaccharides, tetrasaccharides, etc.). Reducing sugars exist in equilibrium in cyclic or linear forms, with cyclic forms generally being preferred. The functionalized sugars of the surfactant portion have functional groups suitable for forming stable covalent bonds with the amino acids of the dual agonist peptide.

[0033] The term "pharmaceutical acceptable" refers to a substance (e.g., active ingredient or excipient) that is suitable for use in contact with the tissues and organs of a subject without undue irritation, allergic response, immunogenicity, and toxicity, is reasonable for a reasonable benefit / risk ratio, and is effective for its intended use. A "pharmaceutical acceptable" excipient or carrier of a pharmaceutical composition is also compatible with the other components of the composition. In one embodiment, a pharmaceutical acceptable composition in which the dual agonist peptide can be formulated includes polysorbate 20 (e.g., about 0.050% (w / w)); optionally, methylparaben (e.g., about 0.300% (w / w)); arginine (about 0.348% (w / w)), and mannitol (e.g., about 4.260% (w / w)) in distilled (DI) water.

[0034] The term "therapeutically effective amount" refers to an amount of a compound that, when administered to a subject, is sufficient to prevent, reduce the risk of developing, delay the onset, slow the progression, or cause regression of the medical condition being treated, or to alleviate to some extent the medical condition or one or more symptoms or complications of that condition in at least a fraction of the subjects receiving the compound. The term "therapeutically effective amount" also refers to an amount of a compound that is sufficient to elicit a biological or medical response in human cells, tissues, or organs that is desired by a physician or clinician.

[0035] The terms "treat", "treating" and "treatment" include alleviating, reversing, inhibiting the progression of, reversing or suppressing a medical condition or one or more symptoms or complications associated with the condition, and alleviating, reversing or eradicating one or more causes of the condition. Reference to "treatment" of a medical condition includes prevention of the condition. The terms "prevent", "preventing" and "prevention" include eliminating the onset of, reducing the risk of onset of, and delaying the onset of a medical condition or one or more symptoms or complications associated with the condition. The term "medical condition" (or simply, "condition") includes diseases and disorders. The terms "disease" and "disorder" are used interchangeably herein.

[0036] The present disclosure also includes a dual agonist peptide product as described herein, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers or excipients. A pharmaceutical composition is provided. The pharmaceutical composition contains a therapeutically effective amount of the peptide product or a suitable fraction thereof. The composition can optionally contain an additional therapeutic agent. In some embodiments, the peptide product is at least about 90%, 95% or 98% pure. Pharmaceutically acceptable excipients and carriers include pharma-ceutically acceptable substances, materials and vehicles. Non-limiting examples of types of excipients include liquid and solid fillers, diluents, binders, lubricants, glidants, surfactants, dispersants, disintegrants, emulsifiers, wetting agents, suspending agents, thickening agents, solvents, tonicity agents, buffers, pH adjusters, absorption retarders, stabilizers, antioxidants, preservatives, antimicrobial agents, antibacterial agents, antifungal agents, chelating agents, adjuvants, sweeteners, flavoring agents, coloring agents, encapsulating agents and coating agents. The use of such excipients in pharmaceutical formulations is known in the art. For example, conventional vehicles and carriers include, but are not limited to, oils (e.g., vegetable oils such as olive oil and sesame oil), aqueous solvents (e.g., saline, buffered saline (e.g., phosphate buffered saline [PBS]) and isotonic solutions (e.g., Ringer's solution)), and organic solvents (e.g., dimethyl sulfoxide and alcohols [e.g., ethanol, glycerol and propylene glycol]). Except insofar as a conventional excipient or carrier is incompatible with the peptide product, the present disclosure encompasses the use of such excipients and carriers in formulations containing the peptide product.See, e.g., Remington: The Science and Practice of Pharmacy, 2lst Ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania) (2005); Handbook of Pharmaceutical Excipients, 5th Ed., Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical Additives, 3rd Ed., Ash and Ash, Eds., Gower Publishing Co. (2007); and Pharmaceutical Pre-formulation and Formulation, Gibson, Ed., CRC Press (Boca Raton, Florida) (2004).

[0037] In an embodiment, the pharmaceutical formulation comprises the peptide product and about 0.025-0.075% (w / w) polysorbate 20, about 0.2-0.5% (w / w) arginine, about 3-6% (w / w) mannitol in deionized water (pH 7.7±0.1); optionally, about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, about 4.260% (w / w) mannitol in deionized water (pH 7.7±0.1). In certain embodiments, the pharmaceutical formulation comprises SEQ ID NO:1 and about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, about 4.260% (w / w) mannitol in deionized water (pH 7.7±0.1). In certain embodiments, the pharmaceutical formulation comprises SEQ ID NO:1 and is configured for subcutaneous administration of a weekly therapeutic dose.

[0038] Suitable or appropriate formulations may depend on various factors, such as the route of administration selected. Potential routes of administration of pharmaceutical compositions containing peptide products include, but are not limited to, oral, parenteral (including intradermal, subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intraperitoneal, intracavity and topical), and topical (transdermal, transmucosal, intranasal (e.g., by nasal spray or drops), intraocular (e.g., by eye drops), intrapulmonary (e.g., by oral or nasal inhalation), buccal, sublingual, rectal (e.g., suppository), and intravaginal (e.g., by suppository)). In certain embodiments, the dual agonist peptide products are administered parenterally (e.g., subcutaneously, intravenously, or intramuscularly). In other embodiments, the peptide products are administered by oral inhalation or nasal inhalation or insufflation. In some embodiments, the carrier is an aqueous-based carrier, such as in a parenteral (e.g., subcutaneous, intravenous, or intramuscular) formulation. In other embodiments, the carrier is a non-aqueous-based carrier. In certain embodiments, the non-aqueous based carrier is a hydrofluoroalkane (HFA) or an HFA-like solvent that may contain submicron anhydrous a-lactose or / and other excipients, such as in formulations for administration by oral or nasal inhalation or insufflation.

[0039] In some embodiments, the peptide product is administered parenterally (e.g., subcutaneously, intravenously, or intramuscularly) by injection. Parenteral administration bypasses the highly acidic environment of the stomach, gastrointestinal (GI) absorption, and first-pass metabolism. Excipients and carriers that can be used to prepare parenteral formulations include, but are not limited to, solvents (e.g., aqueous solvents such as water, saline, physiological saline, buffered saline [e.g., PBS], balanced salt solutions [e.g., Ringer's BSS], and aqueous dextrose solutions), isotonicity / tonicity agents (e.g., salts [e.g., NaCl, KCl, and CaCl] and sugars [e.g., sucrose]), buffers and pH adjusting agents (e.g., sodium dihydrogen phosphate [sodium dihydrogen phosphate] / disodium hydrogen phosphate [disodium phosphate], citric acid / sodium citrate, and L-histidine / L-histidine HC1), and emulsifiers (e.g., non-ionic surfactants such as polysorbates [e.g., polysorbate 20 and 80] and poloxamers [e.g., poloxamer 188]). Peptide formulations and delivery systems are discussed, for example, in AJ Banga, Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3rd Ed., CRC Press (Boca Raton, Florida) (2015). Excipients can optionally include one or more substances that increase peptide stability, increase peptide solubility, inhibit peptide aggregation, or reduce solution viscosity, or any combination or all thereof.Such agents include hydrophilic amino acids (e.g., arginine and histidine), polyols (e.g., myo-inositol, mannitol, and sorbitol), sugars (e.g., glucose (including D-glucose [dextrose]), lactose, sucrose, and trehalose), osmolytes (e.g., trehalose, taurine, amino acids [e.g., glycine, sarcosine, alanine, proline, serine, b-alanine, and g-aminobutyric acid], and betaines [e.g., trimethylglycine and trimethylamine N-oxide]), and non-ionic surfactants (e.g., alkyl polyglycosides, ProTek® alkyl saccharides (e.g., monosaccharides [e.g., glucose] or disaccharides [e.g., maltose or sucrose] linked to long chain fatty acids or corresponding long chain alcohols), and polypropylene glycol / polyethylene glycol block copolymers (e.g., poloxamers [e.g., Plu ronic™ F-68], and Genapol® PF-10 and variants thereof). Such substances increase peptide stability, so they can be used to increase peptide concentration in the formulation. Higher peptide concentration in the formulation is particularly advantageous for subcutaneous administration, which has a limited volume of bolus administration (e.g., <about 1.5 mL). In addition, such substances can be used to stabilize the peptide during preparation, storage and reconstitution of lyophilized peptide. Exemplary parenteral formulations include peptide product, mannitol, methionine, sodium thioglycolate, polysorbate 20, pH adjuster (e.g., NaOH or / and HC1), and deionized water. Parenteral formulation excipients suitable for use with the dual agonist peptides described herein (e.g., various combinations of excipients including NaCl, etc.) are well known and available to those skilled in the art.

[0040] For parenteral (e.g., subcutaneous, intravenous or intramuscular) administration, a sterile solution or suspension of the peptide product in an aqueous solvent containing one or more excipients can be pre-prepared in advance, for example in a pre-filled syringe of a single-use pen or a pen with a dose counter. Alternatively, the peptide product can be dissolved or suspended in an aqueous solvent, which may optionally contain one or more excipients, before lyophilization (freeze-drying). Just before parenteral administration, the lyophilized peptide product stored in a suitable container (e.g., a vial) can be reconstituted, for example, with sterile water, which may optionally contain one or more excipients. In other embodiments, the agonist peptide product is administered intranasally. The nasal mucosa provides a large surface area, a porous endothelium, a highly vascularized epithelial sublayer and a high absorption rate, thus allowing for high bioavailability. The intranasal formulation may include the peptide product together with excipients such as solubility enhancers (e.g., propylene glycol), humectants (e.g., mannitol or sorbitol), buffers and water, and optionally preservatives (e.g., benzalkonium chloride), mucoadhesives (e.g., hydroxyethylcellulose) or / and permeation enhancers. The intranasal solution or suspension formulation may be administered to the nasal cavity by any suitable means, including, but not limited to, by dropper, pipette, or spray, for example, using a metered dose spray pump. Table 2 shows exemplary excipients for nasal spray formulations.

[0041] [Table 2]

[0042] In further embodiments, the peptide product is administered via pulmonary routes, such as oral or nasal inhalation. Because the lungs serve as the entrance to the systemic circulation, pulmonary administration of drugs can treat pulmonary or / and systemic disorders. The advantages of pulmonary drug delivery include, for example, 1) avoidance of first-pass metabolism; 2) rapid drug action; 3) large surface area of ​​the alveolar region for absorption, high permeability of the lungs (thin air-blood barrier), and rich vasculature of the airways; and 4) reduced extracellular enzyme levels compared to the GI tract due to the large alveolar surface area. Although nasal inhalation can deliver drugs to the systemic circulation transmucosally in the nasal cavity as well as in the lungs, the advantages of oral inhalation over nasal inhalation include deeper penetration / deposition of drugs into the lungs. Oral or nasal inhalation can be achieved, for example, by metered dose inhalers (MDIs), nebulizers, or dry powder inhalers (DPIs). For example, the peptide product can be formulated for aerosol administration to the airways by oral or nasal inhalation. The drug is delivered in small particle sizes (e.g., between about 0.5 microns and about 5 microns), which can be obtained, for example, by micronization, to improve drug deposition in the lungs and stability of the drug suspension. It can be provided in a pressurized pack with a suitable propellant, such as a hydrofluoroalkane (HFA, e.g., 1,1,1,2-tetrafluoroethane [HFA-134a]), a chlorofluorocarbon (CFC, e.g., dichlorodifluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane), or a suitable gas (e.g., oxygen, compressed air or carbon dioxide). The drug in the aerosol formulation is dissolved or, more often, suspended in the propellant for delivery to the lungs. The surfactant portion of the peptide product can perform the function of a surfactant, but the aerosol can also include excipients such as surfactants (which enhance lung penetration by reducing the high surface tension at the air-water interface in the alveoli, emulsify, solubilize or / and stabilize the drug, which may be, for example, a phospholipid such as lecithin) or / as well as stabilizers.For example, an MDI formulation can include a peptide product, a propellant (e.g., an HFA such as 1,1,1,2-tetrafluoroethane) and a co-solvent (e.g., an alcohol such as ethanol), and optionally, a surfactant (e.g., a fatty acid such as oleic acid). An MDI formulation can optionally include a dissolved gas (e.g., C02). After activation of the device, the bursting of the C02 bubbles within the emitted aerosol droplets causes the droplets to break into smaller droplets, thereby increasing the respirable fraction of the drug. As another example, a nebulizer formulation can include a peptide formulation, a chelating agent or preservative (e.g., disodium edetate), an isotonicity agent (e.g., NaCl), a pH buffer (e.g., citric acid / sodium citrate) and water, and optionally, a surfactant (e.g., Tween®, such as polysorbate 80). Drugs can be delivered, for example, by a nebulizer or MDI, with or without a spacer, and the drug dose delivered can be controlled by a metering chamber (nebulizer) or a metering valve (MDI).

[0043] Table 2 shows exemplary MDI, nebulizer, and DPI formulations. Metered dose inhalers (also called pressurized metered dose inhalers [pMDIs]) are the most widely used inhalation devices. A metering valve delivers a precise amount of aerosol (e.g., about 20-100 pL) each time the device is actuated. MDIs typically generate aerosol faster than the user can inhale, and much of the aerosol may be deposited in the mouth and throat. The problem of miscoordination between device actuation and inhalation can be addressed, for example, by using breath-actuated MDIs or regulators. When the device senses the user's inhalation, breath-actuated MDIs (e.g., Easi breathe®) are actuated and expel a drug dose in response. The inhalation flow rate is regulated via an actuator, and the user has time to ensure that the device is actuated during inhalation. In a metered device, the spacer (or valved holding chamber), a tube attached to the mouthpiece end of the inhaler, acts as a reservoir or chamber that holds the drug being nebulized by the inhaler, reducing the rate at which the aerosol enters the mouth, thereby allowing evaporation from larger droplets of propellant. The spacer simplifies the use of the inhaler and increases the amount of drug deposited in the lungs instead of the upper airways. The spacer can be made of an antistatic polymer to minimize electrostatic adhesion of released drug particles to the spacer inner walls. Nebulizers produce aerosol droplets of approximately 1-5 microns. Nebulizers do not require user adjustments between actuation of the device and inhalation, which can have a significant impact on the amount of drug deposited in the lungs. Compared to MDIs and DP Is, nebulizers can deliver larger amounts of drug, albeit over a longer administration time.Examples of nebulizers include, but are not limited to, manual nebulizers, jet nebulizers (e.g., AeroEclipse® II BAN [breath-actuated], CompAIR™ NE-C801 [virtual valve], PARI LC® Plus [breath-actuated] and SideStream Plus [breath-actuated]), ultrasonic nebulizers, and vibrating mesh nebulizers (e.g., Akita2® Apixneb, I-neb AAD system with metering chamber, MicroAir® NE-U22, Omron U22 and PARI eFlow® Rapid). As an example, pulsed ultrasonic nebulizers can aerosolize a fixed amount of drug per pulse and can configure a photoacoustic trigger that allows the user to synchronize each breath to each pulse. For oral or nasal inhalation using a dry powder inhaler (DPI), the peptide product can be provided in the form of a dry fine powder, where the drug particles are of a small size (e.g., between about 0.5 microns and about 5 microns) to improve, for example, the aerodynamic properties of the dispersed powder and drug deposition in the lungs. Particles between about 0.5 microns and about 5 microns are deposited by sedimentation in the terminal bronchioles and alveolar regions. In contrast, the majority of larger particles (>5 microns) do not ride the air stream into the many branches of the airway, but rather are deposited by impaction in the upper airways, including the oropharyngeal region of the throat. DPI formulations can contain drug particles alone or blended with powders of suitable larger bases / carriers, such as lactose, starch, starch derivatives (e.g., hydroxypropylmethylcellulose) or polyvinylpyrrolidine. Carrier particles enhance flowability, reduce agglomeration, improve dose uniformity, and aid in the dispersion of drug particles. DPI formulations can optionally contain excipients such as magnesium stearate or / and leucine, which improve the performance of the formulation by disrupting interparticle bonding (by anti-adhesion action).Powder formulations can be provided in unit dose forms such as capsules (e.g., gelatin capsules) or cartridges in blister packs that can be manually loaded or preloaded into the inhaler.Drug particles can be drawn into the lungs by placing the mouthpiece or nosepiece of the inhaler into the mouth or nose, inhaling sharply and deeply to create turbulent airflow, and then holding the breath for a period of time (e.g., about 5-10 seconds) to allow the drug particles to settle in the bronchial and alveolar regions. When the user activates the DPI and inhales, the airflow through the device creates shear and turbulence, and the inhaled air is introduced into the powder bed, where the static powder blend is fluidized and enters the user's airways. There, the drug particles are separated from the carrier particles by the turbulent flow and carried deep into the lungs, while the larger carrier particles impact the oropharyngeal surfaces and are eliminated. Thus, the user's inspiratory airflow achieves powder deagglomeration and air ionization, determining drug deposition in the lungs. (Passive DPIs require rapid inspiratory flow to deagglomerate drug particles, but rapid inspiration is not recommended because MDIs or nebulizers create turbulence and fast flow rates, increasing drug deposition by impaction in the upper airways.) Compared with MDIs, DPIs (including breath-actuated DPIs) can potentially deliver larger doses of drug and larger size drugs (e.g., macromolecules) to the lungs.

[0044] Lactose (e.g., alpha-lactose monohydrate) is the most commonly used carrier in DPI formulations. Examples include, but are not limited to, DCL 11, Flowlac® 100, Inhalac® 230, Lactohale® 300, Lactopress® SD 250 (spray-dried lactose), Respitose® SV003 and Sorbolac® 400. DPI formulations can contain a single lactose grade or a combination of different lactose grades. For example, fine lactose grades such as Lactohale® 300 or Sorbolac® 400 are not suitable DPI carriers and may need to be blended with coarse lactose grades such as Flowlac® 100, Inhalac® 230 or Respitose® SV003 (e.g., about 1:9 ratio of fine lactose to coarse lactose) to improve flow.

[0045] Tables 3 and 4 show non-limiting examples of lactose grades / types that can be used in DPI formulations. The particle size distribution of the carrier affects the fine particle fraction / dose (FPF or FPD) of the drug, and a high FPF is desired for drug delivery to the lungs. The FPF / FPD is the respirable fraction / dose mass that exits the DPI device with an aerodynamic particle size of <5 microns during inspiration. A high FPF, and therefore good DPI performance, can be obtained from a DPI formulation having, for example, a ratio of about 1:9 of fine lactose (e.g., Lactohale® 300) to coarse lactose (e.g., Respitose® SV003) and an overage of about 20% w / w to avoid drug deposition in the capsule shell or DPI device and deliver essentially all of the drug to the airways.

[0046] [Table 3]

[0047] [Table 4]

[0048] Other carriers in DPI formulations include, but are not limited to, glucose, mannitol (e.g., crystallized mannitol [Pearlitol 110 C] and spray-dried mannitol [Pearlitol 110C] and spray-dried mannitol [Pearlitol 100SD]), maltitol (e.g., crystallized maltitol [Maltisorb P90]), sorbitol, and xylitol. Most DPIs are breath-actuated ("passive"), relying on the user's inhalation to generate an aerosol. Examples of passive DPIs include, but are not limited to, Airmax®, Novolizer®, and Otsuka DPI (compact cake). Air classification technology (ACT) is an efficient passive powder dispersion mechanism utilized in DPIs. In ACT, multiple feed channels generate tangential airflow, which creates a cyclone within the device during inhalation. There are also power-assisted ("active") DPIs (e.g., based on air pressure, impact force, or vibration) that use energy to aid in particle deagglomeration. For example, the active mechanism of the Exubera® inhaler utilizes mechanical energy stored in a spring or compressed air chamber. Examples of active DPIs include, but are not limited to, Actispire® (single unit dose), Aspirair® (multiple doses), Exubera® (single unit dose), MicroDose® (multiple unit doses and electronically active), Omnihaler® (single unit dose), Pfeiffer DPI (single unit dose), and Spiros® (multiple unit doses). The peptide product can also be administered by other routes, such as orally. Oral formulations can contain the peptide product and conventional excipients known in the art, and optionally, an absorption enhancer, such as sodium V-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC). SNAC protects against enzymatic degradation via local buffering and enhances GI absorption. Oral dosage forms (e.g., tablets, capsules, or pills) can optionally have an enteric coating to protect the contents from the strong acids and proteolytic enzymes of the stomach.In some embodiments, the peptide product is delivered from a sustained release composition. As used herein, the term "sustained release composition" encompasses sustained, extended, sustained, delayed, slow and controlled release compositions, systems and devices. In some embodiments, the sustained release composition delivers the peptide product for a period of at least about 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months or more. In some embodiments, the sustained release composition is formulated as nanoparticles or microparticles composed of biodegradable polymers and incorporating the peptide product. In certain embodiments, the biodegradable polymer comprises lactic acid or / and glycolic acid [e.g., L-lactic acid-based copolymers such as poly(L-lactide-co-glycolide) or poly(L-lactic acid-co-D,L-2-hydroxyoctanoic acid)]. In further embodiments, the sustained release composition is in the form of a depot that is generated when a mixture of the peptide product and polymer is injected intramuscularly or subcutaneously into a subject. In certain embodiments, the polymer is or includes PEG, polylactic acid (PLA) or polyglycolic acid (PGA), or copolymers thereof (eg, PLGA or PLA-PEG).

[0049] Pharmaceutical compositions can be presented in unit dosage forms as single doses, where all active and non-active ingredients are combined in a suitable system, and the ingredients do not need to be mixed to form a composition to be administered. Unit dosage forms generally contain a therapeutically effective dose of drug, but can contain appropriate fractions so that a therapeutically effective dose is achieved by ingestion of a plurality of unit dosage forms. Examples of unit dosage forms include tablets, capsules or pills for oral ingestion; solutions in pre-filled syringes of single-use pens or pens with dose counters for parenteral (e.g., intravenous, subcutaneous or intramuscular) injection; and capsules, cartridges or blisters pre-loaded or manually loaded into inhalers. Alternatively, pharmaceutical compositions can be presented as kits, where active ingredients, excipients and carriers (e.g., solvents) are provided in two or more separate containers (e.g., ampoules, vials, tubes, bottles or syringes) and need to be combined to form a composition to be administered. The kit can contain instructions for storing, preparing and administering the composition (e.g., a solution to be parenterally injected). The kit can contain all active and inactive ingredients in unit dosage form, or the active and inactive ingredients in two or more separate containers, and can contain instructions for administering or using the pharmaceutical composition to treat a medical condition disclosed herein. The kit can further contain a device for delivering the composition, such as an injection pen or an inhaler. In some embodiments, the kit contains the peptide product or a pharma- ceutical acceptable salt thereof, or a pharmaceutical composition comprising the same, and instructions for administering or using the peptide product or composition to treat a medical condition disclosed herein, such as insulin resistance, diabetes, metabolic syndrome, cardiovascular disease, obesity (including, but not limited to, "chronic obesity" meaning obesity or a resultant obesity-related condition, such as insulin resistance, diabetes, metabolic syndrome, and / or cardiovascular disease, or a condition associated therewith (e.g., NASH or PCOS).In certain embodiments, the kit further contains a device for delivering the peptide product or composition, such as an injection pen or an inhaler.

[0050] The present disclosure further provides uses of the dual agonist peptide products described herein for preventing and / or treating conditions associated with GLP1R and / or GCGR, such as, but not limited to, insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular disease, and conditions associated therewith, such as NASH and PCOS. In some embodiments, the dual agonist peptide products can be used to treat hyperglycemia, insulin resistance, hyperinsulinemia, prediabetes, diabetes (including types 1 and 2, gestational diabetes, and juvenile diabetes), diabetic complications, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, elevated blood levels of free fatty acids, obesity, metabolic syndrome, syndrome X, cardiovascular disease (including coronary artery disease), atherosclerosis, acute cardiovascular syndromes, ischemia (including myocardial ischemia and cerebral ischemia / stroke), ischemia reperfusion injury (including myocardial and cerebral IRI), infarction (including myocardial infarction and cerebral infarction), angina, heart failure (e.g., congestive heart failure), peripheral vascular disease, thrombosis (e.g., deep vein thrombosis), embolism (e.g., pulmonary embolism), systemic inflammation (e.g., characterized by elevated blood levels of C-reactive protein), and hypertension. Dual agonist peptide products can achieve their therapeutic effects through a variety of mechanisms, including stimulating blood glucose-dependent insulin secretion, increasing insulin sensitivity, stimulating fat burning and reducing body weight. Dual agonist peptide products can also promote, for example, pancreatic beta cell protection, cardioprotection and wound healing.

[0051] The peptide products described herein can be used to treat other conditions associated with insulin resistance or / and obesity. Other conditions associated with insulin resistance or / and obesity include arthritis (e.g., osteoarthritis), back pain, respiratory disorders (e.g., asthma, obesity hypoventilation syndrome [Pickwickian syndrome], and obstructive sleep apnea), skin disorders (e.g., diabetic ulcers, acanthosis nigricans, cellulitis, hirsutism, intertrigo, and lymphedema), digestive disorders (e.g., cholelithiasis [gallstones], gastroesophageal reflux disease [GERD], and gastroptosis), gout, adrenal corticosteroid hypersecretion (e.g., Cushing's syndrome), kidney disorders (e.g., chronic kidney disease), liver disorders (e.g., alcoholic and nonalcoholic fatty liver disease), and the like. The therapeutic effects of the dual agonist peptide products include, but are not limited to, fatty liver disease [FLD], including alcoholic FLD), neurological disorders (e.g., carpal tunnel syndrome, dementia [e.g., Alzheimer's disease and vascular dementia], dyssensory thigh pain, migraine and multiple sclerosis), urological disorders (e.g., erectile dysfunction, hypogonadism and urinary incontinence), polycystic ovarian syndrome, infertility, menstrual disorders, mood disorders (e.g., depression), and cancer (e.g., endometrial, esophageal, colorectal, gallbladder, kidney, liver [e.g., hepatocellular carcinoma], pancreatic and skin [e.g., melanoma] cancer, and leukemia). In certain embodiments, the dual agonist peptide products described herein are used to treat polycystic ovarian syndrome (PCOS). In other embodiments, the peptide products are used to treat chronic kidney disease (CKD), also known as chronic kidney / renal failure (CKF / CRF). The most common causes of CKD are diabetes and long-term uncontrolled hypertension. In further embodiments, the dual agonist peptide product described herein is used to treat fatty liver disease (FLD). In some embodiments, FLD is non-alcoholic fatty liver disease (NAFLD). In certain embodiments, NAFLD is non-alcoholic steatohepatitis (NASH). FLD, also known as hepatic fatty liver, is characterized by excess fat accumulation in the liver. FLD includes alcoholic fatty liver disease (AFLD) and NAFLD. Chronic alcoholism causes fatty liver due to the production of toxic metabolites such as aldehydes during the metabolism of alcohol in the liver. NAFLD is described below.FLD is associated with diabetes, obesity and metabolic syndrome. Fatty liver can develop into cirrhosis or liver cancer (e.g., hepatocellular carcinoma [HCC]). Less than about 10% of patients with cirrhotic AFLD develop HCC, whereas up to about 45% of those without cirrhosis and with NASH develop HCC. HCC is the most common type of primary liver cancer in adults and occurs in the setting of chronic liver inflammation. NAFLD is characterized by fatty liver, which occurs when fat, particularly free fatty acids and triglycerides, accumulate in hepatocytes (fatty liver) due to causes other than excessive alcohol intake, such as overnutrition, high calorie intake, and metabolic dysfunction (dyslipidemia and impaired glucose control). The liver can remain fatty without interfering with liver function, but fatty liver can progress to NASH, a condition in which fatty liver is achieved by subfatty injury with or without inflammation, ballooning of liver cells and fibrosis of the liver. Fibrosis is the strongest predictor of mortality from NASH. NAFLD can be characterized by fatty liver alone; fatty liver with lobular or portal inflammation but not ballooning; fatty liver with ballooning but not inflammation; or fatty liver with inflammation and ballooning. NASH is the most extreme form of NAFLD. NASH is a progressive disease, and about 20% of patients will develop cirrhosis and about 10% will die from liver disease, such as cirrhosis or liver cancer (HCC, etc.). NAFLD is the most common liver disorder in developed countries, and NASH is predicted to be the leading cause of liver transplants in the United States by 2020, replacing hepatitis C. Approximately 12-25% of people in the United States have NAFLD, and NASH affects about 2-5% of people in the United States. NAFLD, including NASH, is associated with insulin resistance, obesity, and metabolic syndrome. For example, insulin resistance contributes to the progression of fatty liver to hepatitis and fibrosis, and ultimately to NASH. Furthermore, obesity promotes and exacerbates NASH, and weight loss can ameliorate NASH.Thus, the peptide products described herein, including GLP-1 receptor (GLP1R) agonists, glucagon receptor (GCGR) agonists and dual GLP1R / GCGR agonists, can be used to treat NAFLD, including NASH. In some embodiments, the dual agonist peptide products used to treat conditions associated with insulin resistance or / and obesity disclosed herein, such as NAFLD (e.g., NASH) or PCOS, are selected from the dual agonist peptide products of SEQ ID NOs: 1-10, and / or derivatives thereof, and pharma- ceutically acceptable salts thereof.

[0052] In some embodiments, the dual agonist peptide(s) can be used to control glycemia while reducing one or more adverse events (i.e., unexpected events that adversely affect patient and / or animal welfare) compared to agonists with disproportionate affinity for GLP-1R and GCGR (e.g., semaglutide). Exemplary non-limiting adverse events include nausea, vomiting, diarrhea, abdominal pain, and / or constipation. Adverse events can also include any known to those of skill in the art, such as those listed in industry resources and / or those otherwise known to those of skill in the art (see, e.g., Medical Dictionary for Regulatory Activities (MedDRA) (Pharm., Med.Transl.Med.2018) and / or Clark, MJ Biomed. Inf., 54, April 2015, pp.167-173). Such adverse events can be determined in humans using standard techniques (e.g., physician examination, surveys / questionnaires) typically used in clinical trials. Compared to the frequency and / or severity of such adverse events occurring upon administration to a subject of an agonist having unequal affinity for GLP-1R and GCGR (e.g., semaglutide), the dual agonist peptides of the present disclosure (e.g., any of SEQ ID NOs: 1-10, or derivatives thereof) can reduce such frequency and / or severity by, for example, 20%, 40%, 50%, 60%, 70%, 80%, 90% higher (up to 100%). In some embodiments, the dual agonist peptides of the present disclosure (e.g., any of SEQ ID NOs: 1-10, or derivatives thereof) do not cause adverse events.

[0053] The dual agonist peptide product can be administered by any suitable route for the treatment of the conditions disclosed herein. Potential routes of administration of the peptide product include, but are not limited to, oral, parenteral (including intradermal, subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intraperitoneal, and topical), and topical (including transdermal, transmucosal, intranasal (e.g., by nasal spray or drops), intraocular (e.g., by eye drops), intrapulmonary (e.g., by oral or nasal inhalation), buccal, sublingual, rectal (e.g., by suppository), and vaginal (e.g., by suppository)). In some embodiments, the peptide product is administered parenterally, such as subcutaneously, intravenously, or intramuscularly. In other embodiments, the peptide product is administered by oral or nasal inhalation or insufflation. The therapeutically effective amount and frequency of administration of the peptide product for treating a condition disclosed herein, as well as the duration of treatment with the peptide product, may depend on a variety of factors, including the nature and severity of the condition, the potency of the compound, the route of administration, the age, weight, general health, sex and diet of the subject, and the subject's response to treatment, and may be determined by the treating physician. In some embodiments, the peptide product is administered parenterally (e.g., subcutaneously (sc), intravenously (iv) or intramuscularly (im)) at a dose of about 0.01 mg to about 0.1, 1, 5 or 10 mg, or about 0.1-1 mg or 1-10 mg, for the treatment of a condition disclosed herein (e.g., one associated with insulin resistance and / or obesity, such as NASH or PCOS) for about one week. In further embodiments, the peptide product is administered parenterally (e.g., sc, iv or im) at a dose of about 0.1-0.5 mg, 0.5-1 mg, 1-5 mg or 5-10 mg, for about one week. In certain embodiments, the peptide product is administered parenterally (e.g., subcutaneously (SC), intravenously (IV) or intramuscularly (IM)) at a dose of about 0.1-1 mg, or about 0.1-0.5 mg or 0.5-1 mg for about one week. One of skill in the art will appreciate that effective doses in mice, or other preclinical animal models, can be adjusted for humans.Thus, by non-proportional adjustment (also called biological adjustment), the dose in a larger animal can be extrapolated from the dose in a mouse to obtain an equivalent dose based on the animal's body weight or surface area.

[0054] The peptide product can be administered at any suitable frequency for the treatment of a condition disclosed herein (e.g., one associated with insulin resistance or / and obesity, such as NASH or PCOS). In some embodiments, the dual agonist peptide product is administered sc or iv, for example, once a day, once every two days, once every three days, twice a week, once a week, or once every two weeks. In certain embodiments, the peptide product is administered SC, IV, or IM, for example, once a week. The dual agonist peptide product can be administered at any time that is convenient for the patient. The dual agonist peptide product can be taken substantially with a meal (e.g., with a meal or within about 1 hour or 30 minutes before or after a meal) or substantially without a meal (e.g., at least about 1 hour or 2 hours before or after a meal). The length of treatment of a medical condition with the dual agonist peptide product can be based, for example, on the nature and severity of the condition and the subject's response to treatment, and can be determined by the treating physician. In some embodiments, the dual agonist peptide product is administered chronically to treat a condition disclosed herein, such as for at least about 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 3 years, 5 years, 10 years or more. The dual agonist peptide product can also be taken ad-hoc (as needed) until clinical symptoms of the condition disappear or a clinical target is achieved, such as blood glucose level, blood pressure, blood levels of lipids, weight or body mass index, waist-to-hip ratio or body fat percentage, or any combination thereof. If clinical symptoms of the condition reappear or clinical targets are not maintained, administration of the dual agonist peptide product can be resumed. The present disclosure provides a method of treating a medical condition described herein, comprising administering to a subject in need of treatment a therapeutically effective amount of a peptide product described herein or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition comprising the same. The present disclosure further provides a peptide product described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising the same, for use as a pharmaceutical.Furthermore, the present disclosure provides the use of the peptide product described herein or its pharma- ceutically acceptable salt in the preparation of medicine.The medicine containing the peptide product can be used to treat any medical condition described herein.The peptide product can be optionally used in combination with one or more additional therapeutic agents.

[0055] The dual agonist peptide products described herein can be administered as the sole active agent or can be optionally used in combination with one or more other dual agonist peptide products and / or additional therapeutic agents for treating any disorder disclosed herein, such as insulin resistance, diabetes, obesity, metabolic syndrome or cardiovascular disease, or any condition associated therewith, such as NASH or PCOS. In some embodiments, the one or more additional therapeutic agents are selected from antidiabetic agents, antiobesity agents (including lipid-lowering agents and satiety-promoting agents), antiatherosclerotic agents, anti-inflammatory agents, antioxidants, antifibrotic agents, antihypertensive agents, and combinations thereof.Antidiabetic agents include AMP-activated protein kinase (AMPK) agonists, including biguanides (e.g., buformin and metformin); peroxisome proliferator-activated receptor gamma (PPAR-α / γ agonists), including thiazolidinediones (e.g., balaglitazone, ciglitazone, darditazone, englitazone, lobeglitazone, netoglitazone, pioglitazone, rivoglitazone, rosiglitazone, and turoglitazone), MSDC-0602K, and saroglitazar (a dual PPAR-α / γ agonist). gamma) agonists; glucagon-like peptide-1 (GLP-1) receptor agonists, including exendin-4, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, taspoglutide, CNT0736, CNT03649, HM11260C (LAPS-exendin), NN9926 (OG9S7GT), TT401, and ZYOG1; alogliptin, anagliptin, dutogliptin, evogliptin, gemigliptin, gosogliptin, linagliptin, omagliptin, omega ... Dipeptidyl peptidase 4 (DPP-4) inhibitors, including ligliptin, saxagliptin, septagliptin, sitagliptin, teneligliptin, trelagliptin, and vildagliptin; sodium-glucose transport protein 2 (SGL-2) inhibitors, including canagliflozin (which also inhibits SGLT1), dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin etabonate, sotagliflozin (which also inhibits SGLT1), and tofogliflozin T2) inhibitors; ATP-dependent K+ of pancreatic beta cells, including luneglitides (e.g., mitiglinide, nateglinide, and repaglinide) and sulfonylureas (first generation (e.g., acetohexamide, carbutamide, chloropropamide, dicyclamide [tolhexamide], metahexamide, tolazamide, and tolbutamide) and second generation (e.g., glibenclamide, glyburide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, and glyclopyramide). +Insulin and its analogs, including fast acting insulins (e.g., insulin asparagines, insulin glulisine and insulin lispro), intermediate acting insulins (e.g., NPH insulin), and long acting insulins (e.g., insulin degludec, insulin detemir and insulin glargine); and / or analogs, derivatives and salts thereof. In certain embodiments, the antidiabetic agent is or comprises a biguanide (e.g., metformin), a thiazolidinedione (e.g., pioglitazone or rosiglitazone) or an SGLT2 inhibitor (e.g., empagliflozin or tofogliflozin), or any combination thereof. Antiobesity agents include, but are not limited to, appetite suppressants (appetite reducing drugs), including amphetamine, dexamphetamine, amfepramone, clobenzorex, mazindol, phentermine (with or without topiramate) and lorcaserin; satiety promoters, including chorionic neurotrophic factor (e.g., axokine) and longer acting analogs of amylin, calcitonin, cholecystokinin (CCK), GLP-1, leptin, oxyntomodulin, pancreatic polypeptide (PP), peptide YY (PYY) and neuropeptide Y (NPY); lipase inhibitors, including caulerpenine, cetilistat, everactone A and B, estellastine, lipstatin, orlistat, persiquinine, panclicin A-E, valilactone and vibralactone; antihyperlipidemic agents; and analogs, derivatives and salts thereof. Antihyperlipidemic agents include HMG-CoA reductase inhibitors, including statins {e.g., atorvastatin, cerivastatin, fluvastatin, mevastatin, monacolins (e.g., monacolin K (lovastatin), pitavastatin, pravastatin, rosuvastatin, and simvastatin} and flavanones (e.g., naringenin); squalene synthase inhibitors, including lapaquistat, zaragozic acid, and RPR-107393; anthocyanins, avenaciolide, chloroacetylated biotin, cyclodim, diclofop, haloxyfop, soraphen (e.g., soraphen A la), 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA), acetyl-CoA carboxylase (ACC) inhibitors, including CP-640186, GS-0976, and NDI-010976; 7-(4-propyloxy-phenylethynyl)-3,3-dimethyl-3,4-dihydro-2H-benzo[b][1,4]dioxepin; N-ethyl-N'-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]dec-7-yl)piperidin-1-yl]-carbonyl}-1-benzothien-2-yl)urea; 5-(3 -acetamidobut-1-ynyl)-2-(4-propyloxyphenoxy)thiazole; and 1-(3-{[4-(3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]dec-7-yl)piperidin-1-yl]-carbonyl}-5-(pyridin-2-yl)-2-thienyl)-3-ethylurea; fibrates (e.g., bezafibrate, ciprofibrate, clinofibrate, clofibric acid, clofibrate, aluminum clofibrate [alfibrate], clofibride, etofibrate, fenofibrate, PPAR-δ agonists, including perfluoroalkanoic acids (e.g., perfluorooctanoic acid and perfluorononanoic acid), isoflavones (e.g., daidzein and genistein), and perfluoroalkanoic acids (e.g., perfluorooctanoic acid and perfluorononanoic acid); elafibranor (dual PPAR-α / γ agonist), GFT505 (dual PPAR-α / γ agonist), GW0742, GW501516 (dual PPAR-β / δ agonist), soderglitazar (GW677954), MBX-802 PPAR-δ agonists, including 5, and isoflavones (e.g., daidzein and genistein); PPAR-γ agonists, including thiazolidinediones {above), saroglitazar (a dual PPAR-α / γ agonist), 4-oxo-2-thioxothiazolinones (e.g., rhodanine), berberine, honokiol, perfluorononanoic acid, cyclopentenone prostaglandins (e.g., cyclopentenone 15-deoxy-A-prostaglandin J2 [15d-PGJ2]), and isoflavones (e.g., daidzein and genistein);Liver X receptor (LXR) agonists, including endogenous ligands (e.g., oxysterols such as 22(i?)-hydroxycholesterol, 24(A)-hydroxycholesterol, 27-hydroxycholesterol, and cholestanoic acid) and synthetic agonists (e.g., acetyl-podocarpic acid dimer, hypocholamide, A(X-dimethyl-3b-hydroxy-cholenamide [DMHCA], GW3965, and T0901317); endogenous ligands (e.g., 9-cis-retinoic acid) and synthetic agonists (e.g., bexarotene, AGN 191659, AGN 191701, AGN retinoid X receptor (RXR) agonists, including 192849, BMS649, LG100268, LG100754, and LGD346; inhibitors of acyl-CoA cholesterol acyltransferase (ACAT, acastrol G-acyltransferase [SOAT], including ACAT1 [SOAT1] and ACAT2 [SOAT2]), including avasimibe, pactimbe, pellitorin, terpendol C, and flavanones (e.g., naringenin); inhibitors of stearoyl-CoA desaturase-1 (SCD-1, acastearoyl-CoA delta-9 desaturase) activity or expression, including aramchol, CAY-10566, CVT-11127, SAR-224, SAR-707, XEN-103 toxic agents;3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide;1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine];5-fluoro-1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine];6-[5-(cyclopropylmethyl)-4,5-dihydro-1'H,3H-spiro[1,5-benzoxazepine-2,4'-piperidine]-1'-yl]-N-(2-hydroxy-2-pyridin-3-ylethyl)pyridazine-3-carboxamide;6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide;4-(2-chlorophenoxy)-N-[3-(methylcarbamoyl) phenyl]piperidine-1-carboxamide; conjugated cis-9, trans-11 and trans-10, cis-12 isomers of linoleic acid, substituted heteroaromatic compounds, antisense polynucleotides and peptide-nucleic acids (PNAs) targeting SCD-1 mRNA, and SCD-1 targeting siRNA, as disclosed in WO 2009 / 129625 A1; anacetrapib, dalcetrapib, evacetrapib, torcetrapib, and AMG cholesteryl ester transfer protein (CETP) inhibitors, including 899 (TA-8995); inhibitors of microsomal triglyceride transfer protein (MTTP) activity or expression, including implitabide, lomitapide, dirlotapide, mitratapide, CP-346086, JTT-130, SLx-4090, antisense polynucleotides and PNAs targeting MTTP mRNA, MTTP-targeting microRNAs (e.g., miRNA-30c), and MTTP-targeting siRNAs; GLP-1 receptor agonists; fibroblast growth factor 21 (FGF21), including BMS-986036 (pegylated FGF21). and its analogs and derivatives; berberine (which reduces PC8K9 levels), annexin A2 (which inhibits PCSK9 activity), anti-PCSK9 antibodies (e.g., alirocumab, bococizumab, evolocumab, LGT-209, LY3015014, and RG7652), peptides that mimic the epidermal growth factor-A (EGF-A) domain of the LDL receptor that binds to PCSK9, PCSK9-binding adnectins (e.g., BMS-962476), antisense polynucleotides and PNAs that target PCSK9 mRNA, and PCSK9-targeting siRNAs (e.g., inclisiran [ALN-PCS] and ALN-P; CS02); inhibitors of protein catalyzed convertase subtilisin / kexin type 9 (PCSK9) activity or expression; apoA-I mimetics (e.g., 2F, 3F, 3F-1, 3F-2, 3F-14, 4F, 4F-P-4F, 4F-IHS-4F, 4F2, 5F, 6F, 7F, 18F, 5A, 5A-C1, 5A-CH1, 5A-CH2, 5A-H1, 18A, 37pA [18A-P-18A], ELK, ELK-1A, ELK-1F, ELK-1K1A1E, ELK-1L1K, ELK-1W, ELK-2A, ELK-2A2K2E, ELK-2E2K, ELK-2F, ELK-3 apolipoprotein mimetic peptides, including E3EK, ELK-3E3K3A, ELK-3E3LK, ELK-PA, ELK-P2A, ELKA, ELKA-CH2, ATI-5261, CS-6253, ETC-642, FAMP, FREL, and KRES, and apoE mimetics (e.g., Ac-hEl8A-NH2, AEM-28, Ac-[R]hEl 8 A-NH2, AEM-28-14, EpK, hEp, mRl8L, COG-112, COG-133, and COG-1410); omega-3 fatty acids, including docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), a-linolenic acid (ALA), fish oils (e.g., containing DHA and EPA), and esters thereof (e.g., glyceryl and ethyl esters);and analogs, derivatives and salts thereof. In certain embodiments, the antiobesity agent is or includes a lipase inhibitor (e.g., orlistat) or / and an antihyperlipidemic agent (e.g., a statin, such as atorvastatin, or / and a fibrate, such as fenofibrate). The antihypertensive agent is a renin inhibitor (e.g., aliskiren), angiotensin-converting enzyme (ACE) inhibitor (e.g., benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril and trandolapril), angiotensin II receptor type 1 (ATII1) antagonist (e.g., azilsartan, candesartan, eprosartan, fimasartan, antagonists of the renin-angiotensin-aldosterone system (RAAS), including irbesartan, losartan, olmesartan medoxomil, olmesartan, telmisartan, and valsartan, and aldosterone receptor antagonists (e.g., eplerenone and spironolactone); loop diuretics (e.g., bumetanide, ethacrynic acid, furosemide, and torsemide), thiazide diuretics (e.g., bendamustine, benzoyl peroxide, and benzoyl peroxide); diuretics, including thiazide-like diuretics (e.g., chlorthalidone, indapamide, and metolazone), cicletanine (an early distal tubular diuretic), potassium-sparing diuretics (e.g., amiloride, eplerenone, spironolactone, and triamterene), and theobromine; dihydropyridines (e.g., amlodipine, calcium channel blockers, including valproate, levamlodipine, cilnidipine, clevidipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine, nisoldipine, and nitrendipine) and non-dihydropyridines (e.g., diltiazem and verapamil); alpha2-adrenergic receptor agonists, including clonidine, guanabenz, guanfacine, methyldopa, and moxonidine;α1-adrenergic receptor antagonists (alpha blockers), including doxazosin, indoramin, nicergoline, phenoxybenzamine, phentolamine, prazosin, terazosin, and tolazoline; β-adrenergic receptor (β1 or / and β2) antagonists (beta blockers), including atenolol, betaxolol, bisoprolol, carteolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, oxprenolol, penbutolol, pindolol, propranolol, and timolol; mixed alpha / beta blockers, including bucindolol, carvedilol, and labetalol; selective ETA receptor antagonists (e.g., ambrisentan, atrasentan, edonentan, sitaxsentan, zibotentan, and BQ-123) and dual ET; A / ET Bendothelin receptor antagonists, including antagonists (e.g., bosentan, macitentan, and tezosentan); hydralazine, minoxidil, theobromine, sodium nitroprusside, organic nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate, and nitroglycerin, which are converted to nitric oxide in the body), endothelial nitric oxide synthase (eNOS) stimulators (e.g., cicletanine), activators of soluble guanylate cyclase (e.g., cinaciguat and riociguat), phosphodiesterase PDE5 inhibitors (e.g., avanafil, benzamidenafil, dasantafil, dynafil, lodenafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, dipyridamole, papaverine, propentofylline, zaprinast, and T-1032), prostaglandin Ei (alprostadil) and its analogs (e.g., limaprost and misoprostol), prostacyclin and its analogs (e.g., ataprost, berapid, lost [e.g., esveraprost], 5,6,7-triol-4,8-inter-w-phenylene-9-fluoro-PGl2, carbacyclin, isocarbacyclin, clinprost, ciprostene, eptaloprost, cicaprost, iloprost, pimilprost, SM-10906 (des-methylpimilprost), naxaprostene, taprostenyl, treprostinil, CS-570, OP-2507, and TY-11223), non-prostanoid prostacyclin receptor agonists (e.g., other vasodilators, including, for example, l-phthalazinol, ralinepag, selexipag, ACT-333679 [MRE-269, the active metabolite of selexipag], and TRA-418), phospholipase C (PLC) inhibitors and protein kinase C (PKC) inhibitors (e.g., BIM-1, BIM-2, BIM-3, BIM-8, chererythrine, cicletanine, gossypol, myabenol C, myricitrin, ruboxistaurin, and verbascoside); minerals, including magnesium and magnesium sulfate;and its analogs, derivatives and salts.In certain embodiments, the antihypertensive drug is or comprises a thiazide or thiazide-like diuretic (e.g., hydrochlorothiazide or chlorthalidone), a calcium channel blocker (e.g., amlodipine or nifedipine), an ACE inhibitor (e.g., benazepril, captopril or perindopril) or an angiotensin II receptor antagonist (e.g., olmesartan medoxomil, olmesartan, telmisartan or valsartan), or a combination thereof.In some embodiments, the peptide product described herein is used in combination with one or more additional therapeutic agents for treating NAFLD, such as NASH.In some embodiments, the one or more additional therapeutic agents are selected from antidiabetic agents, antiobesity agents, anti-inflammatory agents, antifibrotic agents, antioxidants, antihypertensive agents, and combinations thereof. Therapeutic agents that can be used to treat NAFLD (e.g., NASH) include PPAR-δ agonists (e.g., MBX-8025, elafibranor [dual PPAR-α / δ agonist] and GW501516 [dual PPAR-β / δ agonist]) and PPAR-γ agonists (e.g., thiazolidinediones such as pioglitazone, and saroglitazar [dual PPAR-α / γ agonist]). PPAR agonists, PPAR-δ and -γ agonism increase insulin sensitivity, PPAR-α agonism reduces hepatic steatosis, and PPAR-δ agonism reduces inhibits activation of macrophages and Kupffer cells;farnesoid X receptor (FXR) agonists, such as obeticholic acid and nonsteroidal FXR agonists like GS-9674, which reduce hepatic gluconeogenesis, lipid synthesis, hepatic steatosis and fibrosis;fibroblast growth factor 19 (FGF19) and its analogs and derivatives, such as NGM-282-FGF19 analogs, which reduce hepatic gluconeogenesis and hepatic steatosis;fibroblast growth factor 21 (FGF21) and its analogs and derivatives, such as BMS-986036 (pegylated FGF21)-FGF21 analogs, which reduce hepatic steatosis, cell damage and fibrosis;HMG-CoA reductase inhibitors, including statins (e.g., rosuvastatin) - statins reduce steatohepatitis and fibrosis; ACC inhibitors, such as NDI-010976 (liver targeting) and GS-0976 - ACC inhibitors reduce lipid biosynthesis and hepatic steatosis; SCD-1 inhibitors, such as aramchol - SCD-1 inhibitors reduce hepatic steatosis and increase insulin sensitivity; SGLT2 inhibitors, such as canagliflozin, ipragliflozin and luseogliflozin - SGLT2 inhibitors reduce body weight, hepatic ALT levels and fibrosis; CCR2 or / and CCR5 antagonists, such as cenicriviroc - antagonists of CCR2 (binds CCL2 [MCP1]) and CCR5 (binds CCL5 [RANTES]) inhibit activation and migration of inflammatory cells (e.g., macrophages) to the liver and reduce liver fibrosis; apoptosis signaling regulators Apoptosis inhibitors, including kinase 1 (ASK1) inhibitors (e.g., selonsertib) and caspase inhibitors (e.g., emricasan [pancaspase inhibitor]), reduce hepatic steatosis and fibrosis; Lysyl oxidase-like 2 (LOXL2) inhibitors, such as simtuzumab, LOXL2 is a key substrate enzyme in collagen formation and is highly expressed in the liver; Galectin-3 inhibitors, such as GR-MD-02 and TD139, galectin-3 is important in the development of hepatic fibrosis; Antioxidants, including vitamin E (e.g., a-tocopherol) and scavengers of reactive oxygen species (ROS) and free radicals (e.g., cysteamine, glutathione, melatonin and pentoxifylline [also anti-inflammatory via inhibition of TNF-a and phosphodiesterase]), reduce hepatic steatosis, hepatocyte ballooning and lobular inflammation;and analogs, derivatives and salts thereof. In some embodiments, the peptide products described herein are used in combination with a PPAR agonist (e.g., a PPAR-δ agonist such as elafibranor or / and a PPAR-γ agonist such as pioglitazone), an HMG-CoA reductase inhibitor (e.g., a statin such as rosuvastatin), an FXR agonist (e.g., obeticholic acid) or an antioxidant (e.g., vitamin E), or any combination thereof, to treat NAFLD (e.g., NASH). In certain embodiments, the one or more additional therapeutic agents for the treatment of NAFLD (e.g., NASH) are or include vitamin E or / and pioglitazone. As will be appreciated by those skilled in the art, other combinations may also be used.;

[0056] Pharmacokinetic ("PK") parameters can be estimated using Phoenix® WinNonlin® version 8.1 or higher (Certara USA, Inc., Princeton, New Jersey). A non-compartmental approach consistent with the extravascular route of administration can be used for parameter estimation. Individual plasma concentration-time data can be used for pharmacokinetic calculations. In addition to parameter estimates for individual animals, descriptive statistics (e.g., mean, standard deviation, coefficient of variation, median, minimum, maximum) can be determined as needed. Concentration values ​​below the dose limit can be treated as zero for the determination of descriptive statistics and pharmacokinetic analysis. Embedded concentration values ​​below the fixed quantification limit can be excluded from the pharmacokinetic analysis. All parameters can be derived from individual dual agonist peptide (or derivatives and / or metabolites thereof) concentrations in plasma from the test article dose groups on the dosing day (Day 1). Parameters can be estimated using nominal dose levels, unless out-of-specification dose formulation analysis results are obtained, in which case actual dose levels can be used. Parameters can be estimated using nominal sampling times, and if biochemical analysis sampling deviations are documented, the actual sampling times at the affected time points can be used. Biochemical analysis data can be used directly for pharmacokinetic analysis and presented in tables and figures in units provided. Pharmacokinetic parameters can be calculated and presented in units provided by the laboratory (e.g., h * ng / mL to h * (The number of decimal places may be adjusted appropriately for presentation in the report, e.g., converted to μg / mL). Descriptive statistics (e.g., mean, standard deviation, coefficient of variation, median, minimum, maximum) and pharmacokinetic parameters may be determined to three significant figures, as appropriate. Additional data processing items may be described, as appropriate. Whenever data permit, PK parameters to be determined are the following: max : Maximum observed concentration; DN C max :dose normalized maximum concentration, C max Calculated as / dose;T max: Time of maximum observed concentration; AUC 0-t : Area under the curve from time 0 to the time of the last measurable concentration, calculated using the linear trapezoidal rule; AUC 0-96 : Area under the curve from time 0 to time 96, calculated using the linear trapezoidal rule; DN AUC 0-96 :dose normalized AUC 0-96 , AUC 0-96 Calculated as / dose; AUC 0-inf : Area under the curve from time 0 to infinity (day 1 only), AUC 0-inf =AUC 0-t +C t / λ z (wherein, C t is the last observed quantifiable concentration, λ z is the disappearance rate constant);t 1 / 2 : Elimination half-life, ln(2) / λ z Additional parameters and comparisons that will be understood by one of skill in the art (e.g., sex ratio, dose proportionality ratio, etc.) can also be determined.

[0057] In some embodiments, the present disclosure provides pharmaceutical dosage formulation(s) comprising at least one dual agonist peptide having affinity for the Glucagon-Like Peptide 1 Receptor (GLP-1R) and the Glucagon Receptor (GCGR), wherein the peptide is modified with a hydrophobic surfactant; the formulation is configured to control blood glucose and / or induce weight loss with reduced one or more adverse events compared to an agonist having disproportionate affinity for GLP-1R and GCGR, the adverse events being selected from nausea, vomiting, diarrhea, abdominal pain and constipation upon administration to a mammal. In some embodiments, the dual agonist peptide is any one of SEQ ID NOs: 1-10, or derivatives thereof, or combinations thereof. In some embodiments, the dual agonist peptide has approximately equal affinity for GLP-1R and GCGR, and in a more preferred embodiment, is SEQ ID NO: 1. In some embodiments, administration of the dual agonist peptide to a mammal results in lower blood glucose about 48 hours or about 96 hours after administration (optionally at least 10, 20, 30, 40, or 50% lower, preferably at least about 50% lower); lower blood glucose about 72 hours after administration (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower); and / or lower blood glucose about 120 hours after administration, compared to administration of an approximately equimolar dosage of semaglutide. In some embodiments, administration of the dual agonist peptide to a mammal induces total body weight loss and / or induces liver weight loss, compared to administration of an approximately equimolar dosage of semaglutide. In some embodiments, administration of the dual agonist peptide to a mammal exhibits a lower Cmax (optionally at least about 10, 20, 30, 40, 50% lower, preferably at least about 50% lower) compared to administration of an approximately equimolar dosage of semaglutide; max (optionally at least any of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100% higher, preferably at least about 100% higher); (0-inf)(optionally at least about 50, 60, 70, 80, 90, 95, 100%, preferably at least about 80-90%, e.g., about 85-93%); 1 / 2(hr) exhibits a prolonged MRT(hr) (optionally at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, preferably at least about 50 or 75%, e.g., about 50-75%); exhibits a prolonged MRT(hr) (optionally at least about 10, 20, 30, 40, or 50% higher, preferably at least about 25% higher); exhibits a sustained PK / PD profile; exhibits equal or higher glucoregulatory activity; induces higher total body weight loss, optionally about twice as high. induce lower body fat mass (optionally any of about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower); and / or, when administered to treat NASH, induce increased total body weight loss, liver weight loss, improved NAS score, improved hepatic biliary steatosis, improved ballooning, improved col1A1 staining, improved ALT, improved hepatic TG / TC, and improved plasma TG / TC. In some embodiments, administration of the dual agonist peptide to a mammal results in a greater weight loss (optionally at least about 10, 20, 30, 40, or 50% greater, preferably at least about 15% greater) by about 14 days after administration of the formulation compared to administration of an approximately equimolar dosage of semaglutide; and / or results in a greater weight loss (optionally at least about any of 10, 20, 30, 40, or 50%, preferably at least about 25% greater) by about 20-28 days after administration of the formulation. In some embodiments, administration of the dual agonist peptide to a mammal results in a weight loss in an obese mammal sufficient to return the mammal to the normal weight range for lean normal mammals compared to administration of an approximately equimolar dosage of semaglutide.

[0058] "Reducing" or "reducing" a side effect or event refers to reducing the severity, duration, and / or frequency of side effects experienced by a subject after administration of an agonist with approximately balanced affinity to GLP1R and GCGR, as well as the incidence in a group of subjects, compared to an agonist with disproportionate affinity to GLP1R and GCGR. Such reduction includes the prevention of some side effects that a subject would experience in response to an agonist with disproportionate affinity to GLP1R and GCGR. Such reduction also includes the elimination of side effects previously experienced by a subject after administration of an agonist with disproportionate affinity to GLP1R and GCGR. In some embodiments, "reducing" or "reducing" a side effect includes the reduction of gastrointestinal side effects, where adverse events are reduced to zero or undetectable levels. In other embodiments, side effects are reduced to levels comparable to untreated subjects, but are not completely eliminated. Furthermore, administration of analogs with disproportionate affinity for GLP-1R or GCGR to mammals may require excessively high doses to maximally activate receptors that are less sensitive to the ligand, thus exceeding biologically effective dose levels for other ligands and potentially causing dose-related undesirable side effects.

[0059] The disclosure also provides a method for lowering and / or stabilizing blood glucose in a mammal, the method comprising administering to the mammal a dual agonist peptide of SEQ ID NO: 1-10 (or a derivative thereof), preferably a dual agonist peptide having approximately equal affinity for GLP-1R and GCGR (preferably SEQ ID NO: 1), which reduces the incidence or severity of one or more adverse events compared to an agonist having unequal affinity for GLP-1R and GCGR (e.g., semaglutide), wherein the adverse events, upon administration to the mammal, are selected from nausea, vomiting, diarrhea, abdominal pain and constipation. In some embodiments, such methods provide lower blood glucose (10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 50% lower) about 48 hours or about 96 hours after administration, lower blood glucose (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower) about 72 hours after administration, compared to methods in which an approximately equimolar dosage of semaglutide is administered. ), and / or results in lower blood glucose (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower) about 120 hours after administration; induces total body weight loss, and / or induces liver weight loss; lower Cmax (optionally at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 50% lower), approximately equal to or higher T max (Optionally, about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% higher T max ), with similar AUC (0-inf) (Optionally, at least about 50, 60, 70, 80, 90, 95, 100%, preferably at least about 80-90%, e.g., about 85-93%, of the T 1 / 2(hr)resulting in a prolonged MRT(hr) (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, preferably at least about 25% prolonged); resulting in a sustained PK / PD profile; resulting in approximately equal or greater glucoregulatory activity; resulting in greater total body weight loss (optionally about 2-fold greater total body weight loss); resulting in lower body fat mass (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower); resulting in greater weight loss (optionally at least 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% lower, preferably at least about 100% lower) by about 14 days after administration of the formulation. , 40, 50, 60, 70, 80, 90, or 100% higher, preferably at least about 15% higher); by about 20-28 days after administration of the formulation, a high weight loss (optionally, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% higher, preferably at least about 25% higher); and / or a weight loss in an obese mammal sufficient to return the mammal's weight to within the normal range of a lean normal mammal; and / or, when the method is for treating NASH, an increased total body weight loss, liver weight loss, improved NAS score, improved hepatobiliary steatosis, improved ballooning, improved col1A1 staining, improved ALT, improved liver TG / TC, and improved plasma triglycerides (TG) / total cholesterol (TC).

[0060] In some embodiments, the disclosure provides a pharmaceutical dosage formulation comprising an agonist peptide product (e.g., SEQ ID NO: 1) and about 0.025-0.075% (w / w) polysorbate 20, about 0.2-0.5% (w / w) arginine, about 3-6% (w / w) mannitol in deionized water (pH 7.7±0.1). In a preferred embodiment, the pharmaceutical dosage formulation is ALT-801 comprising SEQ ID NO: 1, about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, and about 4.260% (w / w) mannitol in deionized water (pH 7.7±0.1).

[0061] In some embodiments, the present disclosure provides a pharmaceutical dosage formulation configured to administer an agonist peptide product (e.g., SEQ ID NO: 1) to a mammal at less than about 0.15 mg / kg / dose, optionally about 0.03-0.10 mg / kg / dose. In some embodiments, the pharmaceutical dosage formulation is configured to administer an agonist peptide product to a mammal at less than 0.15 mg / kg / dose. In some embodiments, the pharmaceutical dosage formulation is configured to administer 0.03-0.15 mg / kg / dose. In some embodiments, the pharmaceutical dosage formulation can be configured to administer about 0.5-about 10 mg per week; optionally about 1-about 7 mg per week; or optionally about 1-5 mg per week. In some embodiments, the pharmaceutical dosage formulation is configured to administer to a mammal once per week for up to 6 weeks. In some embodiments, the present disclosure provides a pharmaceutical dosage formulation configured such that the time to reach a therapeutic dose is about 4 weeks or less. In some embodiments, the therapeutic dose is C max Approximately 400~1300ng / ml;T max About 10 to about 36 hours; and / or AUC 0-48 Approximately 15,000 to 45,000 hours * Shown is ng / mL.

[0062] In some embodiments, the disclosure provides a method of lowering blood glucose and / or lowering body weight in a human, comprising administering to the human a pharmaceutical dosage formulation comprising SEQ ID NO:1, wherein the occurrence of one or more adverse events is reduced compared to an agonist having disproportionate affinity for GLP-1R and GCGR, the adverse events being selected from nausea, vomiting, diarrhea, abdominal pain and constipation upon administration to a mammal. In some embodiments, the method a) reduces the incidence of one or more adverse events compared to agonists with disproportionate affinity for GLP-1R and GCGR, the adverse events being selected from nausea, vomiting, diarrhea, abdominal pain and constipation upon administration to a mammal; b) results in about 50% lower blood glucose at about 48 or 96 hours after administration, about 100% lower blood glucose at about 72 hours after administration, and / or lower blood glucose at about 120 hours after administration compared to methods in which an approximately equimolar dosage of semaglutide is administered; c) induces total body weight loss and / or induces liver weight loss; d) results in a lower Cmax, or optionally about 50% lower Cmax, compared to methods in which an approximately equimolar dosage of semaglutide is administered; max , or optionally about 100% higher T max yielding a similar AUC (0-inf) or optionally an AUC of about 85-93% (0-inf) approximately equal to or less than T 1 / 2(hr) , or optionally about 50-75% T 1 / 2(hr)provides a prolonged MRT(hr), or optionally at least about 25% longer MRT(hr); provides a sustained PK / PD profile and exhibits equal or increased glucoregulatory activity; provides increased total body weight loss, or optionally about 2-fold total body weight loss; provides low body fat mass, optionally about 100% lower body fat mass; and / or, when the method treats NASH, provides increased total body weight loss, liver weight loss, improved NAS score, improved hepatobiliary steatosis, improved ballooning, improved c e) results in a greater weight loss about 14 days after administration of the formulation, optionally about 15% greater, compared to semaglutide administered at an approximately equimolar dose; and / or a greater weight loss by about 20-28 days after administration of the formulation, optionally about 25% greater; and / or f) results in a weight loss in the obese mammal sufficient to return the mammal's weight to within the normal weight range of a lean normal mammal. In a preferred embodiment, the method is for inducing weight loss.

[0063] In some embodiments, the methods disclosed herein do not include a treatment initiation phase. In other words, the first administered dose is a treatment that does not require titration to avoid severe gastrointestinal side effects. For example, in some embodiments, the methods can include administering one or more first doses (treatment initiation phase) of a peptide of the present disclosure, such as SEQ ID NO: 1, followed by one or more larger second doses of the peptide, each of the first and second doses being administered for one week or more. In some embodiments, the first dose(s) and second dose(s) can be followed by one or more third doses, which may be higher than the second dose(s). The switch from the first dose, second dose, and third dose can be made on a weekly basis. For example, if the first dose is found not to induce lower blood glucose and / or weight loss after one week or more, then a higher second dose can be administered for one week or more, followed by analyzing the effect of the second dose(s). If no beneficial effect (e.g., reduction in blood glucose and / or weight) is observed, the second dose can continue to be administered. If no beneficial effect is observed, a third dose can be administered for one or more weeks, followed by determining the beneficial effect. If no adverse events are observed with each dose, this cycle of administration and analysis can be repeated as necessary. In some embodiments, since glycemic control (e.g., reduction in blood glucose) has not been achieved about four weeks after administration of one or more first doses, a subsequent one or more higher second doses of peptide can be administered. In some embodiments, one or more first doses can be administered without the intention of producing a therapeutic effect (e.g., reduction in blood glucose and / or weight loss). However, in some embodiments, the method can be performed without including a treatment initiation phase.

[0064] In some embodiments, the method can be a first-line indication for glycemic control and / or weight loss in humans, meaning that it is the first and only active agent administered to a patient for the purpose of inducing glycemic control and / or weight loss in humans. In some embodiments, the method disclosed herein can include diet and / or exercise adjunct therapy. In such embodiments, a human can be administered the pharmaceutical dosage formulation and can be provided with diet and / or exercise instructions that can enhance the beneficial effects of the pharmaceutical dosage formulation. In some embodiments, the human to whom the pharmaceutical dosage formulation is administered has type 2 diabetes. In some embodiments, the human can exhibit established cardiovascular disease with or without type 2 diabetes.

[0065] In some embodiments, the pharmaceutical dosage formulation is administered approximately every week. In some embodiments, the pharmaceutical dosage formulation is administered to a human approximately every week for about 2 weeks to about 82 weeks or more. In some embodiments, the pharmaceutical dosage formulation administered to a human as a weekly administration for about 4 weeks to about 8 weeks, optionally about 6 weeks, compared to administration of an approximately equimolar dosage of semaglutide, results in a higher total body weight loss about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, or about 7 weeks after administration to the human. In some embodiments, the pharmaceutical dosage formulation is administered on about 1, 8, 15, 22, 29, and 36 days. In some embodiments, the method may include administration of a single dose to a human, compared to administration of an approximately equimolar dosage of semaglutide, results in lower blood glucose about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, or about 7 days after administration. In some embodiments, methods that may involve weekly administration to a human for about 4 to about 8 weeks, optionally about 6 weeks, compared to administration of an approximately equimolar dosage of semaglutide, result in greater total body weight loss about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks or about 7 weeks after administration. In some embodiments, methods that may involve administration of a single dose to a human, compared to administration of an approximately equimolar dosage of semaglutide, show a lower Cmax about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days after administration. In some embodiments, the method can include administering the pharmaceutical dosage formulation to an adult human at about 0.5 mg / dose, about 1.0 mg / dose, about 1.5 mg / dose, about 2.0 mg / dose, about 2.5 mg / dose, about 3.0 mg / dose, about 3.5 mg / dose, about 4.0 mg / dose, about 4.5 mg / dose, about 5.0 mg / dose, or about 5.5 mg / dose. In some embodiments, the pharmaceutical dosage formulation can be administered about once a week or once every two weeks, optionally for at least one month, optionally where each dose contains about the same amount of agonist peptide product. In some embodiments, the pharmaceutical dosage formulation can be administered subcutaneously. In some embodiments, one or more of the doses can be administered via a first route (e.g., subcutaneously) followed by administration by a different route (e.g., orally). In some embodiments, the time to reach a therapeutic dose is about 4 weeks or less.In some embodiments, administration of the pharmaceutical dosage formulation provides a Cmax of about 400 to about 1300 ng / ml;T. max About 10 to about 36 hours; and / or AUC 0-48 Approximately 15,000 to 45,000 hours * In some embodiments, administration of about 1.8 mg of a pharmaceutical dosage formulation containing SEQ ID NO: 1 administered once a week for at least 6 weeks (preferably subcutaneously) results in a total body weight loss of more than about 3-5% over the population to which the formulation is administered, preferably more than about 5%, and / or a net change from placebo of about 6%, preferably about 6.3%. In some embodiments, administration of about 1.2 mg of a pharmaceutical dosage formulation containing SEQ ID NO: 1 administered once a week for at least 6 weeks (preferably subcutaneously) results in a total body weight loss of about 2%, preferably about 1.8% total body weight loss ("average weight loss") over the population to which the formulation is administered, and / or a net change from placebo of about 3%, preferably about 2.7%. The present disclosure also provides further results, which are also preferred embodiments, as shown in Table 7 (weight loss) and / or Table 8 (adverse events). In some embodiments, its administration to a mammal results in weight loss in the obese mammal sufficient to return the human to the normal range for lean normal humans. In some embodiments, the pharmaceutical dosage form is an aqueous formulation comprising one or more of polysorbate 20, arginine, or mannitol.

[0066] Other aspects of the present disclosure are also contemplated and will be recognized by those of skill in the art.

[0067] All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs, unless otherwise defined or clearly indicated otherwise by its usage. As used herein and in the appended claims, the word "a" or "an" means one or more. As used herein, the word "another" means second or more. The acronym "aka" means alternatively (also known as). As used herein, the term "exemplary" means "serves as an example, illustration, or illustration." Any embodiment or feature characterized herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments or features. In some embodiments, the term "about" or "approximately" means within ±10% or ±5% of the stated value. Whenever the term "about" or "approximately" precedes the first number in a series of two or more numerical values ​​or a series of two or more numerical ranges, the term "about" or "approximately" applies to each numerical value in that series of numerical values ​​or in that series of numerical ranges. Ranges may be expressed herein for a particular value and / or for another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations, it will be understood that the particular value forms another embodiment by use of the antecedent about or approximately. It will further be understood that the endpoints of each range are significant both in relation to the other endpoint and independently of the other endpoint. A range (e.g., 90-100%) is meant to include not only the range itself, but also each individual value within the range, as if each value were listed individually. Optionally or alternatively means that the event or circumstance described thereafter may or may not occur, and the description includes instances where the event or circumstance occurs and instances where it does not occur.All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0068] Certain embodiments are further described in the following examples, which are provided by way of example only and are not intended to limit the scope of the claims in any way. EXAMPLES

[0069] Example 1 Peptide synthesis There are many standard protecting groups and coupling agents that can be successfully used in a typical N-alpha-Fmoc-based peptide synthesis. Typical examples are given in U.S. Pat. No. 9,856,306 B2, which is incorporated by reference in its entirety into the present disclosure. Further examples can be found in many reviews and protocols, such as those published by Novabiochem and regularly updated online, as well as in more specialized reviews (e.g., Behrendt, R. et al. (2015) J Peptide Sci 22: 4-27 and references therein). Herein, a typical commercial protocol used by many peptide synthesis contract laboratories was used for the synthesis. A more specific protocol is given below.

[0070] Preparation of C-Terminal Amide Analogue - SEQ ID NO:1 Boc-His(Trt)-Aib-Gln(Trt)-Gly-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(tBu)-Tyr(tBu)-Ser(tBu)-Lys(Boc)-Tyr(tBu)-Leu-Asp(tBu)-Glu * -Lys(ivDDE)-Ala-Ala-Lys *A sample of -Glu(tBu)Phe-Ile-Gln(Trt)-Trp(Boc)-Leu-Leu-Gln(Trt)-Thr(tBu)-Rink amide resin (SEQ ID NO: 1) was prepared by sequential addition of N-alpha-Fmoc protected amino acids using standard coupling protocols such as diisopropylcarbodiimide (DIC) / hydroxybenzotriazole (HBT) coupling followed by standard deprotection with piperazine and next step coupling (Glu * and Lys * demonstrated side chain cyclic lactam attachment, achieved by deprotection of the allyl-based side chain protection using Pd(PPh3)4 / 1,3-dimethylbarbituric acid catalyst, washing with DIPEA and 0.5% sodium diethyldithiocarbamate trihydrate and DIPEA in NMP, then coupling with DIC / Oxyma). Deprotection of the ivDDE group at the Lys-N-epsilon position of residue 17 by incubation with 2% or more hydrazine hydrate in DMF, followed by washing with DMF / CHCl2 and acylation of the Lys side chain with tert-butyl 18-([beta-D-glucuron-1-yl]oxy)octadecanoate in DMF / CHCl2 by use of DIC / HBt or other coupling agents. Completion of the coupling was confirmed with ninhydrin, and the product was washed extensively with CHCl2.

[0071] The resulting resin was subjected to final deprotection and cleavage from the resin by treatment with a cleavage cocktail (94% TFA:2% EDT;2% HO;2% TIS) for 240 min at room temperature. The mixture was treated with EtO to precipitate the product, which was washed extensively with EtO to give the crude title peptide product after drying in vacuum.

[0072] Purification is performed en bloc by reversed-phase (C18) HPLC. The crude peptide is loaded onto a 4.1 x 25 cm HPLC column at a flow rate of approximately 15 mL / min (CH3CN organic modifier in 0.1% aqueous trifluoroacetic acid, buffer A; CH3CN with 0.1% TFA, buffer B) and eluted using a gradient of 40-70% Buffer B. The product fractions are lyophilized and the title product peptide (SEQ ID NO: 1) is obtained with a purity of >94% by analytical HPLC (10.5 min; 40-70% CH3CN in 0.1% TFA) / mass spectrometry (M+1 peak = 1937.44; observed molecular weight 3872.88). In a similar manner, other analogs of the invention were prepared using glucuronic acid or melibiuronic acid prepared as shown in the Examples.

[0073] The analytical data are shown in Table A.

[0074] [Table 5]

[0075] Compounds are analyzed by HPLC / MS to obtain purity and identity data (molecular ion detection). The HPLC technique utilizes analytical columns packed with the listed materials of the listed particle sizes, and data are reported here as k' values ​​(k'=(Tr-T0) / T0), which are expected to be largely independent of system configuration and dead volume, but dependent on gradient and packing material. All compounds were reported to be approximately 95% pure.

[0076] The corresponding 1-methyl and 1-octyl analogs of the title compound are prepared in a similar manner, but using the reagents 1'-methyl β-D-glucuronic acid and 1'-octyl β-D-glucuronic acid (Carbosynth). The corresponding 1-decyl, 1-dodecyl, 1-tetradecyl, 1-hexadecyl, 1-octadecyl, and 1-eicosyl, as well as further analogs, are prepared as described above, using the corresponding mono- and disaccharide uronic acids. Alternatively, 1-alkylglucuronyl, or other uronic acylated analogs, can be prepared by first purifying the deprotected or partially deprotected peptide, followed by acylation with the desired uronic acid reagent. Alternatively, 1-alkylglucuronyl, or other uronic acylated analogs, can be prepared by first purifying the recombinantly prepared peptide, followed by selective acylation of the side chain amino functionality with the desired uronic acid reagent.

[0077] A. 1-Alkyl β-d-glucuronic acid. Common oxidation methods. To a solution of 1-dodecyl β-d-glucopyranoside [2.0 g, 5.74 mmol] in 20 mL of acetonitrile and 20 mL of deionized water, (diacetoxyiodo)benzene [4.4 g, 13.7 mmol] and TEMPO [0.18 g, 1.15 mmol] were added. The resulting mixture was stirred at room temperature until reaction completion (up to 20 h). The reaction mixture was diluted with water and lyophilized to give the crude product as a white powder of sufficient purity for direct use in coupling to peptide Lys side chains (1.52 g, 73%). In a similar manner, other 1-alkyl β-d-glucuronic or melibiuronic acids were prepared for use in acylation of other peptide products described herein. The corresponding 1-substituted glucosides or melivosides were prepared using the procedures of these examples, but substituting the appropriate chain length dicarboxylic acid starting material to obtain the desired chain length from the synthetic procedures of the examples, e.g., hexadecanedioic acid, dodecanedioic acid, etc., in place of octadecanedioic acid.

[0078] B. 18-(tert-butoxy)-18-oxooctadecanoic acid A suspension of octadecanedioic acid (40 g, 127 mmol) in toluene (500 ml) was heated at 95° C. under nitrogen. To the resulting solution, N,N-dimethylformamide di-tert-butyl acetal (98 g, 434 mmol) was added dropwise over 3-4 h. The reaction was stirred overnight at the same temperature, concentrated to dryness in vacuo, and placed under high vacuum overnight. The resulting solid was suspended in CHCl (200 ml), heated and sonicated, and filtered at RT, washing with CHCl. ​​The filtrate (2) was concentrated to give the product as a solid (45 g, 86%), which was used without further purification.

[0079] C. tert-Butyl 18-hydroxyoctadecanoate A solution of 18-(tert-butoxy)-18-oxooctadecanoic acid (45 g, 121 mmol) in THF was cooled on an ice bath under nitrogen and treated dropwise with borane dimethylsulfide complex (16 ml, 158 mmol). Vigorous gas evolution occurred with the first few milliliters of addition. After the addition, the mixture was allowed to warm slowly to RT and stirred overnight. The reaction was cooled on an ice bath, quenched with saturated aqueous sodium carbonate, diluted with ethyl acetate, and washed with saturated aqueous sodium carbonate. The organic layer was concentrated in vacuo and placed under high vacuum overnight. The residue was dissolved in hot toluene (200 ml) and left at room temperature for several hours. The precipitated diol was removed by filtration through Celite and the cake was washed with toluene. The toluene solution was applied directly to a silica gel column and eluted with 10% ethyl acetate / hexane, then 20% ethyl acetate / hexane, then 30% ethyl acetate / hexane, and concentrated to give the product (24 g, 51%) as an oil that solidified on standing. 1 H NMR (500 MHz, d4-MeOH): δ = 3.64 (m, 2H), 2.21 (t, 2H, J = 9), 1.44 (s, 9H) 1.50-1.62 (m, 4H), 1.20-1.40 (m, 27H)

[0080] D. tert-Butyl 18-([1-beta-D-glucos-1-yl]oxy)octadecanoate tert-Butyl 18-hydroxyoctadecanoate (46 g, 129 mmol) was dissolved in toluene (400 ml), concentrated in vacuo to approximately 250 ml, and allowed to warm to room temperature under nitrogen. To this solution was added HgO (yellow) (22.3 g, 103 mmol), HgBr2 (37 g, 103 mmol) and acetobromoglucose with vigorous stirring. Stirring was continued overnight until the alcohol was consumed, and the mixture was filtered through Celite. The filtrate was treated with copper(II) triflate (1 g) and stirred for 1 h until the orthoester (spot on product on TLC) had decomposed. The reaction was then washed with water and the organic layer was concentrated in vacuo. The residue was dissolved in methanol (500 ml) and treated with 0.5 ml portions of sodium methoxide (5.4 M in methanol) to a pH of 9 (spot directly on pH paper). The pH was checked every 0.5 h and further sodium methoxide was added as necessary to maintain the pH at 9. The reaction was complete within 4 h. Acetic acid was added dropwise to bring the pH to 7, and the mixture was concentrated in vacuo. The residue was loaded onto silica gel and purified by silica gel chromatography eluting with 5% methanol / CH2Cl2 then 10% methanol / CH2Cl2 to give the product as a white solid (55 g, 82%). 1 H NMR (400 MHz, d4-MeOH): δ = 4.30 (d, 1H, J = 7.6), 3.84 (m, 1H), 3.77 (d, 1H, J = 9.6), 3.45-3.60 (m, 2H), 3.36 (t, 1H, J = 9.2), 3.21 (t, 1H, J = 8.4), 2.20 (t, 2H, J = 7.2), 1.50-1.67 (m, 4H), 1.43 (s, 9H), 1.43-1.33 (m, 2H), 1.28 (br s, 24H)

[0081] E. tert-Butyl 18-([beta-D-glucuron-1-yl]oxy)octadecanoate tert-Butyl 18-([1-beta-D-glucos-1-yl]oxy)octadecanoate (50 g, 96 mmol) was dissolved in dioxane (800 ml) in a 2000 ml three-neck flask with mechanical stirring and cooled to 10°C. To the solution was added 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) (150 mg, 0.96 mmol) and KBr (1.14 g, 9.6 mmol). A dropping funnel containing saturated Na2CO3 solution (300 ml) and 13% NaOCl solution (120 ml) was fixed to the flask. The carbonate solution was added dropwise rapidly and NaOCl was added dropwise slowly (approximately 1 drop / sec). After the addition of 100 ml of carbonate, the pH was checked and more was added as necessary to maintain a pH of around 10. The temperature was maintained between 10°C and 15°C throughout. After 3 hours, starting material remained so more NaOCl (10 ml) was added quickly. After 0.5 hours the reaction was quenched with methanol (10 ml). The mixture was poured into a 4000 ml Erlenmeyer flask, immersed in an ice bath and adjusted to pH 3 with 6N HCl. The mixture was diluted with ethyl acetate and washed twice with 1N HCl and distilled water, separating the layers after the last wash. The organic layer was concentrated in vacuo to give the product as a white foam (38 g, 74%).

[0082] Quantitative 1H NMR (500 MHz, d4-MeOH) using 2,3,4,5-tetrachloronitrobenzene (TCNB) internal standard for the anomeric CH gives 94.8% of the expected weight. Purity >95% by TLC (20% MeOH / DCM / 2 drops HOAc, staining with 20% H2SO4 / EtOH + heating). 1 H NMR (500 MHz, d4-MeOH): δ = 4.30 (d, 1H, J = 9.5), 3.85 (m, 1H), 3.77 (d, 1H, J = 7.5), 3.48-3.56 (m, 2H), 3.37 (t, 1H, J = 11.5), 3.21 (t, 1H, J = 9.5), 2.20 (t, 2H, J = 9.5), 1.52-1.66 (m, 4H), 1.44 (s, 9H), 1.34-1.42 (br, 2H), 1.28 (s, 25H).

[0083] Example 2 Dual agonist peptides - in vitro assay Cellular assays were performed using standard cell assays (DiscoveRx, LeadHunter assays) with readouts of cAMP stimulation or arrestin activation. Compounds were accurately weighed to approximately 1 mg amounts and shipped to DiscoverX (Fremont, CA) for dilution and assay. The assays used were for glucagon (human, cloned into CHO cells) and GLP-1 (human, cloned into CHO cells) receptors in cell assays. Assays were performed in the presence of 0.1% ovalbumin. Historically, such assays have been performed in the presence of 0.1% BSA, but for those compounds that bind very tightly to serum albumin (>99%), this can skew the results and make the compound much less effective. The use of 0.1% ovalbumin circumvents this issue. The improvement seen when using ovalbumin can be seen as an indication of the relative tightness of serum albumin binding to the peptide.

[0084] [Table 6]

[0085] The assay was performed in the presence of 0.1% ovalbumin. Historically, such assays have been performed in the presence of 0.1% BSA, but for those compounds that bind very tightly to serum albumin (>99%) this can skew the results and make the compound much less effective. The use of 0.1% ovalbumin circumvents this issue. The improvement seen when using ovalbumin can be seen as an indication of the relative tightness of serum albumin binding to the peptide, see the table below.

[0086] [Table 7]

[0087] Here, it can be seen that a very tight serum albumin binder (with a CO2H-containing substituent mimicking the head group of a fatty acid) shows a substantial doubling improvement upon replacement of BSA with ovalbumin, which does not specifically bind to the fatty acid mimic. The degree of doubling improvement gives a reading of the tightness of binding to the fatty acid binding site on BSA. Thus, semaglutide improves by 12-fold (tight binding), whereas EU-A1873 improves by 30-40x, indicating a significant increase in serum albumin binding. This degree of serum albumin binding would be expected to result in suppression of Cmax and an increased duration of action, as seen in the bioassay of SEQ ID NO:1.

[0088] The data presented in Tables 5 and 6 above show that the test compound is an agonist of both GLP-1R and GCGR ("dual agonist"), unlike semaglutide, which shows a biased high affinity for GLP-1. The data also show that SEQ ID NO:1 is a dual agonist peptide with approximately equal affinity for GLP-1R and GCGR.

[0089] Example 3 A clinical trial to determine the safety and tolerability of single and repeated SC administration of ALT-801 in healthy overweight and obese subjects and to characterize the effective dose range based on PK-PD relationships This study included healthy overweight and obese subjects (BMI 25.0-40.0 kg / m 2The study is designed to evaluate the safety and tolerability of single and repeated SC administration of ALT-801 in obese and obese subjects and to characterize the effective dose range based on pharmacokinetic-pharmacodynamic (PK-PD) relationships. Overweight and obese healthy volunteers are studied as PK in such subjects may differ from PK in normal weight individuals. Furthermore, these subjects may better tolerate the expected PD effects of weight loss and may even benefit from treatment. Appropriate contraceptive measures are taken to minimize the possibility of pregnancy, and preventative measures are taken to exclude pre-existing conditions that expose subjects to the risks of treatment with GLP-1 or glucagon analogs. Diabetic subjects were excluded until the effects of ALT-801 on glucose homeostasis have been better characterized in non-diabetic populations. Since overweight and obese subjects are expected to have varying levels of insulin resistance, the observations obtained in these studies, taken together with data on other compounds in this class, should predict the effects observed when studying diabetic subjects. Exclusions were made that may affect the accurate assessment of the safety, PK or PD effects of ALT-801. Analyses will be performed to evaluate the effects on PK and PD parameters of the range of BMI utilized in this study. This study will demonstrate the effects of ALT-801 on body weight and support its use as a first-line treatment for obesity.

[0090] The primary objective of this study is to evaluate the safety and tolerability of ALT-801 in healthy overweight and obese subjects after single and multiple ascending subcutaneous (SC) dose administration by assessing adverse events (AEs), vital signs, clinical safety lab, urinalysis, physical examination, and injection site reactions; glucose homeostasis; blood pressure; electrocardiogram (ECK), Holter monitoring, etc. Secondary objectives of the study are to evaluate 1) the PK of ALT-801 after single and multiple ascending SC dose administration, and 2) the PD effects of ALT-801 after single and multiple dose administration. Exploratory objectives of the study include 1) the extension of PD effects by ALT-801 after multiple dose administration, and 2) the effect of ALT-801 on heart rate corrected QT interval (QTc) prolongation. Study assessments will be based on ALT-801's expected PD properties, including weight loss and changes in body composition, including liver fat content by MRI-PDFF, body weight, body composition by whole-body MRI, insulin resistance, systemic inflammation, and GLP-1 and glucagon target engagement. Measurements of glucose homeostasis will be based on the potential effects of GLP-1 and glucagon analogs on glucose control. 24-hour ambulatory blood pressure monitoring (ABPM) and Holter monitoring will be included, as GLP-1 and glucagon agonists have been associated with clinically insignificant changes in blood pressure and heart rate. Holter monitoring will also be included to provide information on ALT-801's potential effects on QT interval prolongation. Based on experience with the pharmacology and safety of GLP-1 and GLP-1 / glucagon dual agonists, dose-related occurrence of GI AEs, including nausea and vomiting, may occur. Glucose homeostasis will also be assessed, including the incidence and severity of hyperglycemia and hypoglycemia. Efficacy will be monitored rather than safety, as weight loss is a desired property of this compound. However, if weight loss is deemed excessive, doses in subsequent cohorts may be adjusted. Study dosing may be suspended or discontinued in individual subjects if the level of weight loss is deemed unsafe or excessive. Subjects will also be monitored for drug-induced liver injury.Blood samples will be collected before and after the last dose of study drug for biobanking in separately consented subjects. These samples will be used to discover and / or validate biomarkers, including potential genetic analyses, in NASH and related diseases.

[0091] The study described herein is a first-in-human (FIH), Phase 1, randomized, double-blind, placebo-controlled, two-part study of single ascending dose (SAD) and multiple ascending dose (MAD) of ALT-801 in healthy overweight and obese subjects. Overweight to obese subjects (body mass index [BMI] 25.0-40.0 kg / m2) will be enrolled. In part 1, the single ascending dose (SAD) phase, subjects will undergo a screening period of up to 28 days. Overweight to obese subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomized in a 3:1 ratio in cohorts of eight subjects, with six subjects receiving ALT-801 and two subjects receiving placebo. The study drug (SEQ ID NO: 1 formulated as ALT-801 for SC administration) will be administered subcutaneously (SC) in the abdomen in all SAD cohorts. Subjects will be admitted to the research unit approximately 1 day prior to study drug administration (day -1) and discharged on day 8. Subjects will receive a single SC dose of ALT-801 or placebo on day 1. Six cohorts are planned, with two additional optional cohorts for part 1. The following dose levels are planned: weekly doses of 0.4, 1.2, 2.4, 4.8, 7.2, and 9.4 mg administered once per week (QW) based on a 60 kg human. These doses may be modified based on clinical observations or, when available, PK data. The first two subjects (one ALT-801, one placebo) of each SAD cohort will be dosed in a sentinel fashion at least 48 hours prior to the remaining subjects. Subjects will fast overnight and standardize diets for at least 10 hours prior to assessments on days 1-5 and on day 8. Subjects will undergo study evaluations to assess safety, including ECG, CGM, and ABPM, and blood samples will be taken for PK as described in the assessment schedule below. After discharge from the study unit, subjects will have outpatient visits and undergo PK and safety assessments every 3 days through Day 26, with follow-up visits on Day 35 or at least 5 half-lives as determined during the dosing period. Up to two additional single-dose cohorts will be enrolled in Part 1 if the predicted effective dose and exposure based on pharmacological modeling is not achieved and / or the maximum tolerated dose (MTD) for a single dose has not been identified after completion of the six planned cohorts.Following completion of Day 8 in SAD Cohort 3 and evaluation of safety in that cohort, the multiple ascending dose (MAD) phase of Part 2 will begin. The starting dose in Part 2 will generally be half the dose in SAD Cohort 3.

[0092] After informed consent, overweight to obese subjects will be screened for up to 28 days. Subjects will be instructed to maintain their usual diet and activity during the screening period and not to start any new diet, supplement, or exercise programs at any time during their participation in the study. Subjects will enter the study unit approximately 4 days prior to study drug administration (Day-4) and enter a diet and exercise run-in period during which they will consume a standardized diet. The standardized diet will be provided with calories per day that are individualized using predicted BMR x 1.5, accounting for differences between subjects based on weight, height, age, and sex. Activity levels of study participants will also be standardized. Subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomized in a 5:1 ratio on Day -1 into cohorts of 12 subjects, with 10 subjects receiving ALT-801 QW and 2 subjects receiving placebo QW for 6 weeks. Study drug will be administered subcutaneously (SC) in the abdomen in all MAD cohorts.

[0093] Subjects receive their first dose of study drug on day 1 and remain in the study unit until receiving their second dose on day 8. Subjects then return for three outpatient visits at weekly intervals (days 15, 22, and 29) and are readmitted until days 32-43. Subjects receive their final dose of study drug on day 36. After discharge on day 43, subjects return for follow-up on day 70 or 5 half-lives post-dose, whichever comes first. Subjects undergo several study assessments to evaluate the safety, PD, and PK of ALT-801 as described herein. Safety assessments include ECG, CGM, ABPM. PD assessments include anthropometry, dietary assessment, imaging, and blood sampling for biomarkers. The Patient Assessment of Gastrointestinal Disorder Symptom Severity Index (PAGI-SYM) is performed to evaluate the effect of treatment on GI symptoms. Blood samples are collected for PK and immunogenicity. Subjects will fast overnight for at least 10 hours prior to days -1 through 5 and days 7, 8, 36, 37, 42, and 43. In addition, subjects will consume a standard breakfast for the mixed meal tolerance test on days -1, 7, and 42.

[0094] The MAD dose will be selected based on clinical data and, when available, PK data from previously completed SAD and MAD cohorts. Three MAD cohorts are planned, with up to two additional cohorts included as needed, to achieve predicted effective dose and exposure based on pharmacometric modeling, to expand previously studied dose levels, to continue dose escalation if no MTD is identified for this phase, or to consider dose escalation schemes if GI intolerance is observed before reaching the maximum effective dose based on pharmacometric modeling.

[0095] The maximum recommended starting dose (MRSD) for Part 1 was based on one-tenth the human equivalent dose (HED) at the NOAEL determined in animals (rats and monkeys) in drug safety studies. Both rats and monkeys were expected to have similar clinical responses to ALT-801, but the exposure at the NOAEL was slightly lower in rats, leading to a more conservative starting dose in humans. The rat NOAEL was a high dose of 0.45 mg / kg / week, which is equivalent to 0.44 mg / week in a 60 kg human based on body surface area scaling. Of note, the NOAEL in monkeys was also a high dose of 0.25 mg / kg, which is equivalent to 0.49 mg / week in a 60 kg human based on body surface area scaling. Using a 10-fold scaling factor for safety, a human starting dose of 0.40 mg / week was selected for a 60 kg human. Furthermore, human exposures estimated at the maximum recommended starting dose (MRSD) are well below those at the monkey NOAEL and are particularly similar to those at the rat NOAEL. This is particularly important because monkeys, although not the most sensitive species, are the more biologically relevant species for the most clinically relevant toxicities (i.e., reduced food intake and vomiting). Clinical observations and PK in Part 1 will ultimately guide dosing considerations in Part 2.

[0096] The primary finding of ALT-801 in rat and monkey studies was weight loss (see, e.g., Example 4). Changing the daily dosing schedule to 3 days per week in rats improved tolerability by reducing the effect of ALT-801 on food consumption and weight loss, consistent with the mechanism of action. The toxicity of GLP-1 and glucagon agonists was also well characterized in human studies. Preclinical safety findings support a 3-fold dose escalation to SAD cohort 2. Subsequent dose escalations will not exceed 2-fold in any part of the study. If required to improve tolerability, a dose escalation scheme may be considered. In addition to the reliability of these predictions, we predict that the dose-exposure relationship in humans will be linear based on population PK models of several preclinical animal species (mouse, rat, minipig, and monkey). As studies are ongoing, we will update the model with human data. The predicted t1 / 2 of ALT-801 in humans is in the 100-hour range, and this assumption will be confirmed in part 1. Based on once weekly (QW) dosing, estimated cumulative doses with repeated dosing at steady state are less than 2-fold. To ensure that multiple dose exposures are contained within single dose exposures, the starting dose in Part 2 is planned to be half the dose in Cohort 3 in Part 1. However, subsequent Part 2 cohorts may be adjusted based on safety and PK data. The decision to escalate to each well-metrized dose level is based on evaluation of safety and tolerability through Day 8 of Part 1 (7 days after the single dose) and Day 15 of Part 1 (7 days after the second dose). The decision to escalate beyond week 2 is based on findings from earlier GLP-1 and GLP-1 / glucagon dual agonist studies that AEs, which we expect to be primarily nausea or vomiting, occur during the first 2 weeks of dosing. Additionally, the C max and AUC tau The expected outcome was in the completed and safety-evaluated SAD cohort. Cmax or AUC infBased on pharmacological modeling of animal PK parameters to predict exposure in animals and human PK at effective doses, the target dose for maximum efficacy, corresponding to an ED80-ED90 in adult humans, is estimated to be 1-5 mg, with the target plasma concentration estimated to be 50-100 ng / ml. Thus, the estimated starting dose is approximately 2.5-fold lower than the predicted lowest effective dose and is expected to be ineffective.

[0097] To maximize safety, single ascending dose (SAD) and multiple ascending dose (MAD) escalations are planned not to exceed exposure at the NOAEL in rats. However, if PD and tolerability indicate that overweight and obese subjects would benefit from doses that exceed exposure at the rat NOAEL, supporting safety and efficacy data will be presented to the IEC for consent before continuing with SAD and MAD escalation.

[0098] A minimum of 6 subjects are required for dose escalation in part 1 and 8 subjects are required for dose escalation in part 2, with at least one subject in each cohort receiving placebo. If observations suggest that dose escalation exceeds the MTD, the suggested next dose level may be adjusted based on evaluation of safety and tolerability data observed in previous treatment cohorts. Dosing may proceed until the MTD is identified, which is determined separately for each part of the study. Available PK data may be used to guide decision-making, and will be explicitly considered if exposure is expected to exceed the NOAEL in rats. To maximize safety, the planned SAD and MAD escalations will not exceed exposure at the NOAEL in rats.

[0099] After completion of screening activities, subjects who meet all inclusion criteria and no exclusion criteria will be randomized via an interactive web response system (IWRS). In part 1, two subjects from each cohort will be randomly assigned 1:1 to ALT-801 or placebo treatment for sentinel administration. The remaining six subjects in each cohort of eight subjects will be randomly assigned to ALT-801 or placebo treatment, with five assigned to ALT-801 and one assigned to placebo, for an overall ALT-801:placebo ratio of 3:1 for each cohort. In part 2, the cohort of 12 subjects will be randomly assigned 5:1 to ALT-801 or placebo, with 10 assigned to ALT-801 and 2 assigned to placebo.

[0100] SEQ ID NO:1 will be formulated as ALT-801 in a sterile buffered aqueous solution (e.g., about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, about 4.260% (w / w) mannitol in deionized water (pH 7.7±0.1)) in glass vials containing SEQ ID NO:1 at a final concentration of 2.5 mg / mL and a total fill volume of 1.2 mL, and administered as a subcutaneous (SC) injection. In Part 1, a single dose of study drug will be administered on Day 1. The first two subjects of each SAD cohort (one ALT-801 and one placebo) will be dosed in a sentinel fashion at least 48 hours prior to dosing the remaining subjects. In Part 2, study drug will be administered QW for 6 weeks. Doses will be administered on Days 1, 8, 15, 22, 29, and 36. The starting dose for Part 1 is 0.40 mg, which corresponds to one-tenth of the human equivalent dose at the no observed adverse effect level (NOAEL) in rats (rounded down from 0.44 mg / week for safety), and dose escalation follows a modified Fibonacci scheme, with dose escalation no more than three times the planned dose levels of 0.40, 1.2, 2.4, 4.8, 7.2, and 9.4 mg (equivalent to a weekly dose administered once every 7 days). The starting dose for Part 2 is planned to be one-half the dose of Part 1 cohort 3. However, subsequent Part 2 cohorts may be adjusted based on safety and PK data. The decision to escalate to each successful dose level is based on evaluation of safety and tolerability through Day 8 of Part 1 (7 days after the single dose) and Day 15 of Part 2 (7 days after the second dose). Dose escalation may be modified, and the dose escalation scheme is as needed or as described herein. Each dose of ALT-801 or placebo will be administered as a SC injection in the abdomen by an appropriately trained clinical staff member. Dosage will be chosen based on the dose selected, with a concentration of 2.5mg / mL for the final drug product. The saline placebo will be matched to a volume based on the dose and volume of ALT-801 administered in that cohort. Efficacy rather than safety will be monitored, as weight loss is a desirable attribute of this compound. However, if weight loss is deemed excessive, the dose in subsequent cohorts may be adjusted. If the level of weight loss is deemed excessive, the study drug may be suspended or discontinued in individual subjects.If the level of GI adverse events is deemed excessive and intolerable despite antiemetic treatment (e.g., severe GI AEs lasting >24 hours), study drug may be suspended or discontinued in individual subjects. If vomiting persists, subjects may be administered an antiemetic. In this case, a 5HT3 receptor antagonist (e.g., ondansetron) is preferred. If observations suggest that dose escalation is exceeding the MTD, the recommended dose level may be revised downward based on evaluation of safety and tolerability data observed in previous treatment cohorts. Dosing may proceed until identification of the MTD, which is determined individually for each part of the study. Available PK data may be used to guide decision-making.

[0101] Blood samples will be collected for PK assessment at 0, 1, 4, 6, 8, 12, and 16 hours on days -1, 1, 2, 3, 4, 5, 8, 11, 14, 17, 20, 23, and 26 in part 1, and at 0, 1, 4, 6, 8, 12, and 16 hours on days -1, 1, 2, 3, 4, 5, 8, 15, 22, 29, and 36-38 in part 2. The remaining plasma of the PK samples may be frozen and stored without time restriction and may be used for ALT-801 bioanalytical method development or to explore ALT-801 metabolites. The time of ECG reading will coincide with the PK sample time. If multiple activities occur at the same time point, ECG should be collected first and PK blood should be done at the nominal time. PD assessment will be done only in part 2.

[0102] Height is measured in centimeters using a wall-mounted stadiometer or a stadiometer attached to a balance beam scale, whichever is available. Subjects should be wearing socks or barefoot. Weight is measured in kilograms using a calibrated scale at approximately the same time of day for each nominal time point, except at the screening visit. Measurements should be taken with subjects wearing a gown (or other standard attire provided by the Clinical Research Unit), underwear, and socks (but no shoes) while fasting and after the subject has been instructed to void (i.e., bladder is empty). Waist circumference should be measured with subjects wearing a gown. Measurements are taken at a height midway between the superior aspect of the iliac crest and the lateral inferior border of the ribs. It is not necessary to measure to the level of the umbilicus. The tape measure should be held horizontally. Height, weight, and waist circumference are measured and BMI is calculated and recorded according to the schedule in Parts 1 and 2. Height measurements are required only at screening. Waist circumference is measured for subjects in Part 2 only.

[0103] FibroScan® is an ultrasound-like device that can simultaneously measure liver stiffness and steatosis by vibration-controlled transient elastography (VCTE) and CAP, respectively. For Part 2 subjects, FibroScan® is measured during screening after at least 10 hours of overnight fasting. FibroScan® CAP is measured before MRI-PDFF. MRI-PDFF is a quantitative imaging biomarker that allows accurate and reproducible quantitative assessment of liver fat throughout the liver. For Part 2 subjects, MRI-PDFF is measured during screening (CAP ≥ 300 dB / m) and at the EOS visit after a minimum of 10 hours of fasting. Percent liver fat is corrected for total liver volume, which is measured simultaneously with liver fat content. Whole-body MRI is an established imaging technique used to measure body composition, including lean body mass. For Part 2 subjects, whole-body MRI is performed during screening and at the EOS visit in conjunction with MRI-PDFF.

[0104] In parts 1 and 2, subjects are provided with a standardized diet for the duration of their stay on the study unit. Daily calories are individualized using the predicted BMR equation multiplied by an activity factor of 1.5, and macronutrient composition is standardized at 40-50% carbohydrate, 15-25% protein, and 30-40% fat. In part 2, the same standardized diet is provided on days -4 to -2 and days 39 to 41, prior to PD assessments on days -1 and 42. Timing and type of meals are also specific to ECG, MRI-PDFF, and MMTT assessments, as described in the corresponding manuals, respectively.

[0105] Food intake and appetite are assessed using an ad libitum eating test and a VAS questionnaire. The VAS questionnaire is a standard method in appetite studies that records hunger, satiety, fullness, and desire to eat specific tastes such as sweet, salty, savory, and fatty [Flint 2000]. Subjects complete the VAS questionnaire before and after an ad libitum meal on the days specified in the assessment schedule. The size of the ad libitum meal exceeds the expected intake of healthy overweight and obese volunteers. During the test meal, subjects are isolated and environmental factors are minimized (i.e., no television, cell phones, computers, etc.). Subjects are instructed to consume as much as they want within 30 minutes and to eat until they feel comfortably full. Pre- and post-meal weights are recorded to capture food intake and to determine caloric expenditure.

[0106] Basal metabolic rate (BMR) and resting energy expenditure (REE) are assessed under fasting conditions and in the morning after at least a 10-hour fast. Assessment of resting energy expenditure is performed on days -1 and 42. BMR and REE are measured using the fume hood method (indirect calorimetry). Since BMR is usually the major component of daily energy expenditure, changes to BMR may be of clinical relevance in metabolic drug development programs that target energy expenditure.

[0107] After a minimum of 10 hours of fasting, subjects undergo a mixed meal tolerance test (MMTT) in which they ingest a standardized liquid meal (6 fluid ounces of Ensure Plus [700 kcal], a dietary supplement containing fat, carbohydrate, and protein components that constitute the standard MMTT) within 5 minutes. The sample at t=0 minutes (i.e., before the standardized liquid meal) is the last HOMA IR 2 blood sample (see above). Hormonal markers include glucose, insulin, and C-peptide. Samples are taken at 5-minute intervals for the first 15 minutes, and then for 30 minutes until 240 minutes after the standardized liquid meal (without additional food intake during this time). The MMTT procedure is performed on the days specified in the assessment schedule. To standardize the tests and reduce variability, each test is preceded by a run-in period of 3 days of standardized diet and standardized physical activity after admission to the clinical research unit.

[0108] Blood samples for ketone body assessment are collected after subjects have fasted overnight for at least 10 hours, one day before the first and second doses, and six days after the last dose. Blood samples for FGF-21 and adiponectin assessment are collected after subjects have fasted overnight for at least 10 hours. After a minimum of 10 hours of fasting, blood is collected before the first dose and six days after the last dose of study drug for lipid assessment, including cholesterol (total cholesterol, HDL, LDL), Apo A and B, lipoprotein (a), TG, and tripalmitin, as shown in Table 4. Blood is collected before the first dose and six days after the last dose of study drug for inflammatory marker assessment, including TNF-α, hs-CRP, leptin, MCP-1, and IL-6, as shown in Table 4. Glucose homeostasis is assessed by 24-hour CGM using a Dexcom G6 CGM during the time periods shown in Part 1 and Part 2.

[0109] The safety analysis population includes all randomized subjects who received at least one dose of study drug. Subjects are analyzed by the treatment they received. The PK population includes all randomized subjects who received at least one dose of ALT-801 and have sufficient PK data for analysis. The QT population includes all subjects in the PK population who were included and had at least one time-matched ECG at baseline and a corresponding time-matched PK-ECG after dosing. The PD population includes all randomized subjects who received at least one dose of study drug and had baseline and at least one post-baseline PD assessment.

[0110] Statistical methods used include using descriptive statistics to assess differences in demographic and baseline characteristics. Medical history will be coded using the most recent Medical Dictionary for Regulatory Activities (MedDRA) version and enumerated by subject. Continuous safety data will be outlined using descriptive statistics (mean, standard deviation [SD], median, minimum, and maximum) by dose level and treatment (active or placebo). Categorical safety data will be outlined using frequency counts and percentages by study site, dose level, treatment, and day where available.

[0111] AEs will be coded using the most recent MedDRA version. AE data listings by subject will be provided, including reporter term, preferred term, SOC, treatment, severity, and relationship to study drug. The number of subjects experiencing treatment-emergent AEs (TEAEs) and the number of individual TEAEs and injection site reactions will be outlined by treatment group, SOC, and preferred term. TEAEs will also be outlined by severity (grade 1-4) and relationship to study drug (unlikely, possible, probably). Association with stopping rules will be defined as possibly related or probably related. Clinical laboratory assessments, vital sign assessments, continuous cardiac monitoring, ECG parameters (excluding Holter monitoring), CGM measurements, ABPM measurements, and meal tolerance test parameters will be outlined by study part, treatment group, dose level, and protocol-specified collection time points. A summary of changes from baseline at each protocol-specified time point by treatment group will also be provided. Physical examination changes will be listed for each subject. The analysis of PAGI-SYM will be detailed in the Statistical Analysis Plan (SAP). Concomitant medications will be listed for each subject and coded using the most recent WHO drug dictionary.

[0112] Pharmacokinetics includes individual ALT-801 concentration data listed and outlined by cohort along with descriptive statistics (number of cases [N], mean, SD, coefficient of variation [CV%], median, minimum, and maximum). Also shown are graphs of individual and mean ± SD ALT-801 concentration-time profiles for each cohort. Plasma ALT-801 noncompartmental (NCA) PK parameters Cmax, time to maximum plasma concentration (Tmax), AUC0-t, AUC0-inf, elimination rate constant (Kel), t1 / 2, apparent total body clearance (CL / F), and terminal apparent volume of distribution (Vz / F) (when data are sufficient for parameter determination) are estimated for the SAD part. For the MAD part, Tmax, Cmax, and AUCtau PK parameters are estimated after the first and last dose (weeks 1 and 6). When data permit, Kel, t1 / 2, apparent total body clearance at steady state (CLSS / F) and apparent volume of distribution at steady state (VSS / F) will be estimated after week 6 dosing. Pharmacokinetic parameters will be listed for each individual and outlined by cohort using descriptive statistics (N, arithmetic mean, SD, CV%, median, minimum, maximum, geometric mean, and geometric CV%). The effect of baseline BMI on PK parameters will be assessed by correlation analysis. Dose proportionality will be assessed using a power model approach, as appropriate. Accumulation will be assessed as the ratio of Cmax and AUC0-tau at week 6 to week 1. Steady state will be assessed by comparison of trough concentrations from the first dose to the last dose.

[0113] ECGs extracted from Holter monitors are analyzed in a central ECG laboratory by a select population of experienced readers blinded to subject, visit, procedure, and nominal time points. One reader reviews each subject's ECG unless a second review is required based on quality control or availability. All ECGs are analyzed using the same leads for each subject. The primary analysis lead is Lead II, unless unanalyzable, then V2 or V5 is used for the entire data set for each subject.

[0114] The primary analysis will be the mean change and one-sided 95% upper confidence limit for the change from baseline to post-dose time points, corrected for placebo using Fridericia corrected QT interval (ΔΔQTcF). Other correction methods, such as Bazett's method (QTcB), individual correction (QTcI), or population correction (QTcP), may be considered and compared. At a minimum, Fridericia's correction and Bazett's correction will be analyzed and presented. Secondary analyses will include the relationship between time-matched plasma concentrations and ΔΔQTcF using linear mixed-effects modeling. The immunogenicity of repeat doses of ALT-801 will be assessed by evaluation of serum samples using an ELISA-based assay collected at the final visit of the MAD period. Interim data will also be analyzed if end-of-study samples are positive. Immunogenicity may be correlated with safety and PK, if applicable.

[0115] Pharmacodynamic studies will include changes in hepatic fat content, anthropomorphic parameters, GLP-1 involvement and insulin resistance, glucagon involvement, and lipid and inflammatory markers will be listed and outlined by treatment group using descriptive statistics (number of cases [N], arithmetic mean, SD, median, minimum, maximum, geometric mean, and geometric CV%). Inferential statistics will be applied where applicable. The effect of baseline BMI on PD parameters will be assessed by covariate analysis.

[0116] An interim analysis may be performed after completion of two or more doses in MAD cohort 3. The purpose of this analysis is to enable dose selection for follow-on studies. For this analysis, the study will remain blinded and subject-level safety, PD, and available PK data will be de-identified for analysis. Summary data by study part, dose level, treatment arm (active or placebo), and day when applicable will be reported. Conduct of the interim analysis will be detailed in the SAP.

[0117] Example 4 Phase 1 Study of ALT-801 in Overweight and Obese Volunteers (Interim Data at Week 6) This example presents results from the ALT-801 Phase 1 clinical trial, a placebo-controlled, first-in-human, single ascending dose (SAD) and multiple ascending dose (MAD) study in overweight and obese volunteers, conducted in Australia under a clinical trial application. The primary objective of the study is to evaluate safety, tolerability, pharmacokinetics, and weight loss in ALT-801 recipients compared to placebo administered once weekly for 12 weeks. Dosing in the MAD phase began with cohorts receiving ALT-801 1.2 mg SC or placebo once weekly, progressing through the higher dose cohorts, with subjects in the 1.2 mg and 1.8 mg cohorts now completing 6 weeks of treatment. An interim analysis was performed at 6 weeks of dosing for the first two study cohorts and is presented in this example.

[0118] This study shows that ALT-801 induces rapid and robust weight loss in healthy overweight and obese volunteers. Weight loss results from a pre-specified 6-week interim analysis of an ongoing 12-week Phase 1 placebo-controlled single and multiple ascending dose study of ALT-801 in healthy overweight and obese volunteers are shown in Table 7. Using 1.8 mg subcutaneously (SC) once weekly of ALT-801, the analysis showed that by week 6 (day 43), subjects achieved a mean weight loss of 5.4% (6.3% net change from placebo) compared to a 0.9% weight gain in the placebo group, which exceeds the pre-treatment goal of 2% weight loss (Table 7, Figure 1). All but one of the nine subjects receiving the 1.8 mg SC dose achieved at least 3% weight loss by week 6. The lower-dose cohort receiving 1.2 mg SC weekly achieved a 1.8% weight loss (2.7% net change from placebo) at the same time point.

[0119] [Table 8-1]

[0120] [Table 8-2]

[0121] The study presented in this example also shows that ALT-801 is well tolerated without dose escalation. Adverse event results of a prespecified 6-week interim analysis of an ongoing 12-week Phase 1 placebo-controlled single and multiple ascending dose study of ALT-801 in healthy overweight and obese volunteers are shown in Table 8. The data show that ALT-801 was well tolerated without dose escalation, with rates of transient nausea of ​​14.3% and 22.2% at the 1.2 mg and 1.8 mg doses, respectively, and no reports of vomiting, diarrhea, or constipation at either dose. All nausea at the 1.8 mg dose was mild in severity. These results place ALT-801 among the most effective and well tolerated GLP-1-based therapeutics. Gastrointestinal events have been associated with other GLP-1-based agents requiring titration over 16-20 weeks to remain well tolerated.

[0122] [Table 9-1]

[0123] [Table 9-2]

[0124] [Table 9-3]

[0125] The analysis showed that by week 6, subjects achieved a mean weight loss of 5.4% (6.3% net change from placebo) using 1.8 mg subcutaneously (SC) weekly compared with a 0.9% weight gain in the placebo group, exceeding the pre-study treatment goal of 2% weight loss. All but one of the nine subjects receiving 1.8 mg SC achieved at least a 3% weight loss by week 6. The lower dose cohort receiving 1.2 mg SC weekly achieved a 1.8% weight loss (2.7% net change from placebo) at the same time point. ALT-801 was well tolerated without dose escalation, with rates of transient nausea of ​​14.3% and 22.2% in the 1.2 mg and 1.8 mg groups, respectively, and no reports of vomiting, diarrhea, or constipation at either dose. These results place ALT-801 among the most effective and well-tolerated GLP-1-based therapeutics. Gastrointestinal events have been reported over 16-20 weeks of dose titration, which is longer than other GLP-1-based agents that require adequate tolerability.

[0126] Example 5 ALT-801 (pemvidutide) Phase 1 Study in Overweight and Obese Volunteers - 12-Week Results This example shows the results of a Phase 1 clinical trial with ALT-801 (pembidutide), a placebo-controlled, first-in-human, single ascending dose (SAD) and multiple ascending dose (MAD) study in overweight and obese volunteers, conducted in Australia under a clinical trial application. The primary objective of the study is to evaluate the safety and tolerability, pharmacokinetics, and weight loss in subjects administered ALT-801 compared to placebo administered once weekly for 12 weeks. The study was conducted in the absence of calorie restriction or activity weight loss programs. In certain embodiments, ALT-801 (also known as pembidutide) can be used as a first-line and sole treatment for chronic weight management in obese (i.e., BMI 30 or greater) or overweight (i.e., BMI 25 or greater) subjects. In certain other embodiments, ALT-801 (also known as pembidotide) can be used as adjunctive therapy for chronic weight management in obese (i.e., BMI 30 or greater) or overweight (i.e., BMI 25 or greater) subjects, in combination with a reduced-calorie diet and / or increased physical activity.

[0127] Eligible participants included healthy non-diabetic subjects with a minimum body mass index (BMI) of 25 kg / m2. In the MAD portion of the study, 34 subjects were assigned to receive one of three subcutaneous doses of pemvidutide (1.2 mg, 1.8 mg, and 2.4 mg) or placebo once a week for 12 weeks without dose determination. No behavioral or calorie restriction intervention was administered. Dosing in the MAD phase began with a cohort receiving 1.2 mg SC of ALT-801 or placebo once a week, through a high dose cohort, and subjects in the ALT-801 1.2 mg, 1.8 mg, and 2.4 mg cohorts completed 12 weeks of treatment, as shown in this example. The demographic characteristics of participants in the MAD phase are shown in Table 9.

[0128] [Table 10]

[0129] The results of weight loss after weekly dosing of ALT-801 in healthy overweight and obese volunteers are shown in Table 10. The results show that ALT-801 induces rapid and robust weight loss in healthy overweight and obese volunteers. Using ALT-801 at 1.8 mg subcutaneously (SC) weekly, a mean weight loss of 10.25% was achieved by week 12 (day 85) compared to a mean weight loss of only 1.6% in the placebo group (Table 10, Figure 2). Furthermore, at the 1.8 mg dose, 100% of subjects achieved a weight loss of 5% or more by week 12, and 55% of subjects lost at least 10% of their body weight by week 12 (Figure 2). At week 12, the low dose cohort receiving 1.2 mg SC weekly achieved a weight loss of 4.87%, and the high dose cohort receiving 2.4 mg SC weekly achieved a weight loss of 8.95% (Table 10). At the 2.4 mg dose, all but one subject achieved a 5% weight loss by week 12 (Figure 3). The amount of weight loss at the 1.8 mg and 2.4 mg doses was essentially the same for a given number of cases and overlapping confidence intervals. As shown in Figures 3 and 4, the weight loss trend was maintained through week 12, indicating a higher level of predicted weight loss if dosing were to be maintained for a longer period of time. In contrast, in overweight or obese participants, the mean change in body weight from baseline to week 12 with once-weekly semaglutide 2.4 mg plus lifestyle intervention was only 6% (Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989). Interestingly, there was no significant difference in weight loss at week 12 between the different ALT-801 treatment groups and subjects of different age or BMI (body mass index; kg / m2 ) (Figure 5), meaning that the robust weight loss observed in this study would be expected across all age and weight groups.

[0130] [Table 11-1]

[0131] [Table 11-2]

[0132] [Table 11-3]

[0133] [Table 11-4]

[0134] [Table 11-5]

[0135] [Table 11-6]

[0136] Adverse events for 12 weeks of monitoring are shown in Table 11. The results indicate that ALT-801 is well tolerated without the need for dose escalation. All treatment-emergent adverse events were mild to moderate in nature, resolved with drug treatment, and did not require special treatment. One patient experienced elevated ALT levels, which quickly resolved after cessation of dosing. In particular, gastrointestinal adverse events were mostly transient and mild in nature, and resolved with drug treatment. These gastrointestinal adverse events were also transient in nature, with subjects often experiencing a single episode, and their frequency decreased during the treatment period. No subjects withdrew from the study due to adverse events (see Table 12). Gastrointestinal phenomena required other GLP-1-based agents to determine dose over 16-20 weeks to maintain adequate tolerability. For example, WEGOVY (semaglutide), approved for chronic weight management in adult patients (https: / / www.accessdata.fda.gov / drugsatfda_docs / label / 2021 / 215256s000lbl.pdf), requires a 16-week dose titration from 0.5 mg to 2.4 mg to manage the emergence of adverse events. These results place ALT-801 among the most effective and well-tolerated GLP-1-based therapeutics.

[0137] [Table 12-1]

[0138] [Table 12-2]

[0139] [Table 12-3]

[0140] [Table 12-4]

[0141] [Table 12-5]

[0142] [Table 12-6]

[0143] [Table 12-7]

[0144] [Table 12-8]

[0145] [Table 12-9]

[0146] [Table 13]

[0147] As shown in Table 13, treatment with ALT-801 also tends to show a reduction in systolic and diastolic blood pressure, which are considered biomarkers of cardiovascular risk. In addition, treatment with ALT-801 also tends to lower lipids, which are also considered biomarkers of cardiovascular risk (Table 14). Furthermore, as shown in Table 15, ALT-801 reduces pre-diabetes and metabolic syndrome. Treatment with ALT-801 maintains glucose homeostasis, which indicates that the GLP-1 activity of ALT-801 effectively balances the glucagon effect on blood glucose (Table 16). Table 17 shows the results of ketogenesis, which shows the effect of ALT-801 on increasing fat burning, an effect that can be attributed to the glucagon activity of ALT-801.

[0148] [Table 14]

[0149] [Table 15]

[0150] [Table 16]

[0151] [Table 17]

[0152] [Table 18]

[0153] ALT-801 also exhibits a favorable pharmacokinetic (PK) profile that may support once weekly dosing and be associated with acceptable gastrointestinal tolerability, as shown in Table 18.

[0154] [Table 19]

[0155] In summary, in this study, an impressive 10.3% weight loss was observed after only 12 weeks of treatment with a 1.8 mg subcutaneous dose of ALT-801. This effect was maintained at the 2.4 mg dose. The majority of subjects (55%) at the 1.8 mg dose showed a weight loss of more than 10%. The weight loss trend was maintained through week 12. ALT-801 was well tolerated, with mostly mild adverse events. No treatment led to study discontinuation due to adverse events. The linear rate of weight loss suggests that these effects are sustained. Compared to other GLP-1 receptor-biased agonists such as semaglutide, no dose escalation was required to achieve rapid weight loss, which was accompanied by good patient compliance. In addition, no hyperglycemic AEs and no adverse effects on glycemic control or heart rate were observed.

[0156] Example 6 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Tolerability, Pharmacodynamics, and Pharmacokinetics of ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes The study enrolled overweight and obese patients with T2DM (body mass index (BMI) 28.0 to 40.0 kg / m2) receiving either (1) diet and exercise therapy, (2) metformin with no or mild gastrointestinal symptoms (nausea, vomiting, or diarrhea), and / or (3) sodium glucose cotransporter-2 (SGLT-2) therapy for at least 3 months prior to screening. 2 A Phase 1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801, as well as its effects on glucose control, in subjects (male or non-pregnant female subjects aged 18-65 years with type 2 diabetes mellitus (T2DM) with gefitinib or ketamine-related deficiency (GFR) syndrome. In this study, ALT-801 or placebo will be administered by subcutaneous (SC) (preferably abdominal) injection once weekly for up to 12 doses to patients (e.g., 48 subjects) with type 2 diabetes mellitus (T2DM) for approximately 4.5 months, including a screening period of up to 35 days, a treatment period of 85 days, and a follow-up period of 25 days.

[0157] The primary safety objective is to evaluate the safety and tolerability of ALT-801 in T2DM subjects, and the secondary safety objective is to evaluate the effect of ALT-801 on glycemic parameters and incidence of hyperglycemia and hypoglycemia in T2DM subjects. Primary safety endpoints include adverse events (AEs), vital signs, double product (mean heart rate x mean systolic blood pressure), liver function tests, incidence of hyperglycemic and hypoglycemic adverse events, physical examination, injection site reactions, and immunogenicity. Secondary safety endpoints include change from baseline in glycemic parameters, including fasting serum glucose, CGM parameters (area under glucose concentration-time profile, time in range, and hyperglycemia and hypoglycemia), and HbA1c. Continuous safety data will be summarized by dose level and treatment (active or placebo) using descriptive statistics (arithmetic mean, standard deviation [SD], median, minimum, and maximum). Categorical safety data will be summarized by dose level, treatment group, and day when applicable using frequency counts and percentages. AEs will be coded using the most recent Medical Dictionary for Regulatory Activities (MedDRA) version. Subject-specific AE data listings will be provided, including reporter term, preferred term, system organ class (SOC), treatment, severity, and relationship to study drug. The number of subjects experiencing treatment-emergent AEs (TEAEs), as well as the number of individual TEAEs and injection site reactions will be summarized by treatment group, SOC, and preferred term. TEAEs will also be summarized by severity and relationship to study drug. Clinical laboratory assessments, including liver function tests and fasting serum glucose, vital signs (including calculation of RPP), and ECG assessments will be summarized by treatment group, dose level, and protocol-specified collection time points. A summary of changes from baseline at each protocol-specified time point will also be presented by treatment group. Physical examination changes for each subject will also be listed. Concomitant medications will be listed by subject and coded using the most recent version of the World Health Organization (WHO) drug dictionary. Medical history will be coded using the most recent MedDRA version and listed by subject.

[0158] The primary pharmacodynamic (PD) objectives are to assess the effects of ALT-801 on insulin sensitivity and secretion in T2DM subjects. These include changes in insulin secretion and sensitivity from baseline as measured by MMTT (area under the curve over 4 hours (AUC0-4) for serum glucose, C-peptide, and insulin) and homeostasis model assessment of insulin resistance (HOMA IR) (fasting plasma glucose and insulin). Secondary PD objectives are to assess the effects of ALT-801 on insulin sensitivity and secretion in T2DM subjects. 13 Gastric emptying measured by C-Spirulina breath test (lag phase, half-life, gastric emptying coefficient), anthropometric parameters (e.g., weight, waist circumference, BMI), lipid metabolism (cholesterol (total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein (Apo) A and B, lipoprotein (a), and triglycerides (TG)), metabolic markers (leptin, adiponectin), inflammatory markers (tumor necrosis factor (TNF), high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor 1 (PAI-1), monocyte chemotactic protein-1 (MCP-1), and interleukin-1 (IL-1)). The objective of this study is to evaluate the effect of ALT-801 on insulin sensitivity and secretion, anthropometric parameters, lipid metabolism, metabolic markers, lipotoxicity markers, and inflammatory markers. Changes in insulin sensitivity and secretion, anthropometric parameters, lipid metabolism, metabolic markers, lipotoxicity markers, and inflammatory markers will be listed and summarized by treatment group using descriptive statistics (number of cases (N), arithmetic mean, SD, median, minimum, maximum, geometric mean, and geometric coefficient of variation (CV%)). The effect of baseline BMI on PD parameters will be evaluated by covariate analysis. Change data from baseline for lag phase, half-life, and gastric emptying coefficient will be listed and summarized using descriptive statistics (N, arithmetic mean, SD, CV%, median, minimum, and maximum).

[0159] Quality of life (QoL) effects will also be monitored (changes from baseline in Short Form-36 and Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQoL-Lite for CT)). Changes from baseline in the two summary scores for physical health and mental health, the eight domain scores of the SF-36, and the IWQoL-Lite composite score for CT will be enumerated and summarized by treatment group using descriptive statistics (N, arithmetic mean, SD, median, minimum, maximum, geometric mean, and geometric CV%). Inferential statistics applicable to continuous endpoints will be applied as described above.

[0160] Pharmacokinetic (PK) objectives are to assess ALT-801 and metformin concentration change from baseline. Individual ALT-801 and metformin concentration data will be listed and summarized by treatment group and time point with descriptive statistics (N, arithmetic mean, SD, CV%, median, min, and max). Mean ± SD ALT-801 concentration-time profiles for each cohort will be presented graphically. Metformin concentration changes from baseline will be listed and summarized by treatment group and time point with descriptive statistics (N, arithmetic mean, SD, CV%, median, min, and max). Population PK models will be developed to predict individual subject ALT-801 plasma concentration-time curves and associated PK parameters. Covariates including sex, age, weight, BMI, and concomitant medications will be examined wherever possible, and exposure-response relationships will be examined for efficacy and safety endpoints wherever possible.

[0161] After providing informed consent, subjects will undergo a screening period of up to 35 days. Subjects will be instructed on how to maintain their usual diet, alcohol consumption, and physical activity, and not to start any new dietary, supplement, or exercise programs at any time while participating in the study. Diet and exercise counseling will be provided beginning at the Day 8 visit and will be reinforced at each visit during the treatment period. Subjects who meet the inclusion criteria and no exclusion criteria will be randomized 1:1:1:1 to one of the following treatment arms: ALT-801, 1.2 mg, subcutaneous (SC), once weekly for 12 weeks; ALT-801, 1.8 mg, SC, once weekly for 12 weeks; ALT-801, 0.6 mg, SC, in week 1, 1.2 mg, SC, in week 2, 1.8 mg, SC, once weekly for 2 weeks (weeks 3 and 4), and 2.4 mg, SC, once weekly for weeks 5-12; and placebo (0.9% NaCl), SC, once weekly for 12 weeks. Subjects will be stratified by baseline metformin use or absence. There will be 12 subjects in each treatment arm. Subjects will receive their first dose of study medication on day 1. Subsequent visits will occur weekly at the clinic, home, or workplace until day 85 or early termination as per Table 1. Subjects will return for safety follow-up on Day 110. Investigators will follow decision criteria for timing and method of intervention in subjects with worsening liver function test abnormalities during the 12-week treatment period. Subjects will undergo 7-day continuous glucose monitoring (CGM) to measure blood glucose levels at screening, week 5, and the final week of the study. Mixed meal tolerance testing (MMTT) with measurement of glucose and hormonal markers will be performed at screening and at the end of the treatment period. Subjects will also undergo 10-day follow-up at screening (Day -8) and week 8 (Day 50) to assess the effect of ALT-801 on gastric emptying rate. 13C-Spirulina gastric emptying breath test. Fasting blood glucose levels will be measured by glucometer and recorded by study staff at each visit beginning on day -35 and throughout the treatment period. Outside of visit days, subjects will also monitor and record their fasting blood glucose every morning and will contact the study site for any readings >240 mg / dL or <70 mg / dL. Any CGM readings <70 mg / dL during the week when CGM is performed (screening, week 4, and week 12) will be confirmed by a glucometer reading. Subjects will also be educated on the symptoms and treatment of hypoglycemia and will obtain a glucometer reading if they experience a blood glucose level <70 mg / mL or symptoms suggestive of hypoglycemia. Subjects will record any hypoglycemic symptoms experienced at home along with glucometer readings at the time of the event and this will be confirmed by the investigator at each visit. The investigator will counsel the subject on how to maintain fasting blood glucose within limits, including repeated dietary counseling, and will follow decision criteria for timing and method of intervention in subjects with persistent hyperglycemia during the 12-week treatment period. If a significant decrease in fasting blood glucose is observed repeatedly (<50 mg / dL) or the subject requires intervention or external assistance to treat hypoglycemia, the subject may be dropped and replaced from the study. Sparse blood samples will be taken for ALT-801 PK to combine with data from other studies in population PK and PK-PD modeling, and for metformin PK to evaluate metformin concentration over time in the presence of ALT-801. Blood samples will also be taken to evaluate immunogenicity.

[0162] The results of this study indicate that ALT-801 administered by subcutaneous (SC) injection once weekly for up to 12 doses in subjects with T2DM is safe and tolerable, with favorable PD, quality of life, and PK effects, as well as glucose control in subjects.

[0163] Example 7 A Phase 1, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of ALT-801 in Diabetic and Nondiabetic Overweight and Obese Subjects With Nonalcoholic Fatty Liver DiseaseALT-801 is a modified 29 amino peptide with equivalent dual agonist properties at the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR). ALT-801 is being developed for nonalcoholic steatohepatitis (NASH), a subgroup of nonalcoholic fatty liver disease (NAFLD) in which steatosis leads to hepatocellular injury and inflammation (steatohepatitis) with or without fibrosis. In the United States (US), NASH is the leading cause of end-stage liver disease or liver transplantation [Goldberg 2017]. Obesity is a central driver of NASH, and weight loss results in reduced liver fat and amelioration of NASH [Vilar-Gomez 2015]. More than 80% of individuals with NASH are overweight or obese [Diehl 2017], and since there are no currently available US Food and Drug Administration (FDA)-approved pharmacological options to induce weight loss, therapy is largely based on lifestyle interventions aimed at achieving weight loss. However, long-term weight loss is difficult to achieve and maintain through lifestyle modifications alone. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a treatment option for patients with NASH. Liraglutide, a once-daily GLP-1RA, has been associated with resolution of NASH and a trend toward improvement in liver fibrosis [Armstrong 2016]. In a recent trial, semaglutide dosing up to 0.4 mg / day was associated with a mean weight loss of up to 12.5%, along with a significantly higher rate of NASH resolution. A weight loss of 10% or more is considered the cutoff for optimal NASH resolution and fibrosis improvement [Vilar-Gomez 2015]. Higher levels of weight loss are also associated with lower incidence of cardiovascular disease and non-hepatic malignancies, which represent the most serious comorbidities faced by patients with NASH. Unfortunately, the doses of liraglutide and semaglutide utilized in these studies were associated with high rates of gastrointestinal (GI) AEs that may lead to patient discomfort and noncompliance. GLP-1RAs exert central effects on appetite and feeding, while GCGR agonists (GCGRAs) increase energy expenditure in animal models and humans [Lynch 2014].The actions of GCGRA and GLP-1RA have been shown to synergistically promote weight loss compared to GLP-1RA alone [Day 2012]. GCGRA also enhances lipolysis and inhibits hepatic fat synthesis, providing additional pathways for hepatic fat reduction and NASH resolution [Schade 1979]. Dual agonists combine GCGRA with GLP-1RA in the same molecule. In obese non-human primates, chronic administration of a GLP-1RA / GCGRA dual agonist reduced body weight and improved glucose tolerance to a greater extent compared to a GLP-1RA monoagonist [Tschop 2016]. Clinical trials of cotadutide, a GLP-1 / GCGR dual agonist with a 5:1 bias to the glucagon activity of GLP-1, demonstrated a significant reduction in hepatic fat fraction by 39% in just 6 weeks and greater improvement in NASH-associated alanine aminotransferase (ALT) reduction than liraglutide alone. However, the degree of weight loss over 26 weeks of cotadutide treatment was not significantly greater than liraglutide (5.4% vs. 5.5%), suggesting that a 5:1 ratio, while acceptable for liver fat reduction, is suboptimal for weight loss [Alba 2021, Ambery 2018, Nahra 2021, Armstrong 2016]. Balanced (1:1) agonism has been shown to be associated with greater weight loss and metabolic benefits than skewed ratios that favor one agonist over the other [Day 2012]. A recent trial with JNJ 64565111, a balanced dual agonist [Alba 2021], achieved a notable reduction in weight in just 12 weeks (NCT03586830). Evidence suggests that GLP-1RA / GCGRA dual agonists may also exert positive effects on glycemic control [Nahra 2021]. GLP-1 biased GLP-1R and GLP-1-based dual receptor agonists are commonly associated with GI side effects, including nausea, vomiting, and diarrhea [Filippatos 2014]. These agents also need to be titrated over time to reduce side effects [Ambery 2018, Newsome 2020, Frias 2018], necessitating agents with improved tolerability and dosing regimens.Because both GLP-1R and GCGR agonism contribute to weight loss, one might expect less aggressive dosing with a monomolecular GLP-1R / GCGR dual agonist, potentially resulting in a reduced incidence of GI toxicity.

[0164] This example describes the progression of diabetes and nondiabetic overweight and obese patients (body mass index [BMI] 28.0 to 40.0 kg / m) with nonalcoholic fatty liver disease (NAFLD). 2 This paper describes a Phase 1 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety of ALT-801 and its effects on hepatic fat fraction, anthropometric parameters, lipid metabolism, inflammatory markers, and fibrosis markers in diabetic and non-diabetic overweight and obese subjects with NAFLD after 12 weeks of ALT-801 treatment. The study is designed to evaluate changes in hepatic fat fraction by MRI-PDFF in diabetic and non-diabetic overweight and obese subjects with NAFLD after 12 weeks of ALT-801 treatment. The study also evaluates changes in body weight, lipid metabolism, metabolic markers, and inflammatory markers, as well as the safety and tolerability of ALT-801 after 12 weeks of treatment. Subjects are stratified by the presence or absence of diabetes at baseline. The study is designed to evaluate changes in hepatic fat fraction by MRI-PDFF in diabetic and non-diabetic overweight and obese subjects with NAFLD after 12 weeks of ALT-801 treatment. The study also evaluates changes in body weight, lipid metabolism, metabolic markers, and inflammatory markers, as well as the safety and tolerability of ALT-801 after 12 weeks of treatment. Subjects will be stratified by the presence or absence of diabetes at baseline.

[0165] For this study, suitable subjects have NAFLD without significant fibrosis, defined as FibroScan® controlled attenuation parameter (CAP) ≥ 280 dB / m, and liver stiffness measurement (LSM) < 8.5 kPa, and magnetic resonance imaging proton density fat fraction (MRI-PDFF) ≥ 10%. If the subject has type 2 diabetes mellitus (T2DM), they are on a stable regimen of any combination of (1) diet and exercise therapy, (2) metformin with no gastrointestinal symptoms (nausea, vomiting, or diarrhea) or with mild gastrointestinal symptoms (nausea, vomiting, or diarrhea), and / or (3) sodium glucose cotransporter-2 (SGLT-2) therapy for at least 3 months prior to screening. After providing informed consent, subjects are screened for up to 35 days. Subjects are instructed on how to maintain a normal diet, alcohol consumption, and physical activity, and not to start any new diet, supplement, or exercise programs at any time during study participation. Diet and exercise counseling will be provided at the Day 1 visit, with reinforcement of counseling at subsequent visits. Subjects who meet the inclusion criteria and no exclusion criteria will be randomized 1:1:1:1 to one of the following treatment arms: 1) ALT-801, 1.2 mg, SC, once weekly for 12 weeks; 2) ALT-801, 1.8 mg, SC, once weekly for 12 weeks; 3) ALT-801, 0.6 mg, SC, in week 1, 1.2 mg, SC, in week 2, 1.8 mg, SC, once weekly for 2 weeks (weeks 3 and 4), and 2.4 mg, SC, once weekly for weeks 5-12; or placebo (0.9% NaCl), subcutaneous (SC), once weekly for 12 weeks. Subjects will be stratified by the presence or absence of diabetes at baseline. There will be 18 subjects in each treatment arm. Subjects will receive their first dose of study medication on Day 1. Subsequent visits will occur weekly at the clinic, home, or workplace until Day 85 or early termination. Subjects will return for safety follow-up on Day 110. Investigators will follow decision criteria regarding the timing and method of intervention in subjects with worsening liver function test abnormalities during the 12-week treatment period. Fasting plasma glucose (FPG) levels will be measured with a glucometer and recorded by study staff at baseline and before each dose.Even on non-visit days, subjects will monitor and record their FPG every morning and contact the study site for any readings >240 mg / dL or <70 mg / dL. Subjects will also be educated on the symptoms and treatment of hypoglycemia and will have a glucometer reading if they experience plasma glucose <70 mg / mL or symptoms suggestive of hypoglycemia. Subjects will record any symptoms of hypoglycemia experienced at home, which will be reviewed by the investigator at each visit beginning on Day 8. Investigators will counsel subjects on how to maintain FPG within limits, including repeated dietary counseling, and will follow decision criteria for the timing and method of intervention for subjects with persistent hyperglycemia during the 12-week treatment period. Subjects may be dropped and replaced from the study if a significant decrease in FPG is observed repeatedly (FPG <50 mg / dL) or if the subject requires intervention or outside assistance to treat hypoglycemia. Sparse blood samples will be collected for ALT-801 pharmacokinetics (PK) to combine with data from other studies in population PK and PK-PD (pharmacodynamic) modeling, and for metformin PK to assess changes in metformin concentrations over time in the presence of ALT-801. Blood samples will also be collected to assess immunogenicity.

[0166] Safety endpoints included adverse events (AEs), vital signs and double product (RPP calculated as mean heart rate × mean systolic blood pressure), safety tests including liver function tests and serum glucose, urinalysis, physical examination, injection site reactions, and immunogenicity (neutralizing antibodies). Pharmacodynamic (PD) endpoints included change in hepatic fat fraction by MRI-PDFF compared to baseline (relative and absolute % change, percentage of subjects with 30%, 40%, and 50% relative reduction in hepatic fat fraction, percentage of subjects with normalized hepatic fat), anthropometric parameters (weight, waist circumference, and body composition by MRI), lipid metabolism (total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A (Apo A) and B (Apo B)), and pharmacokinetics (pharmacokinetics and pharmacokinetics). The study will include changes from baseline in hepatic fat fraction (HbA1c), lipoprotein(a), triglycerides (TG), metabolic markers (hemoglobin A1c (HbA1c), adiponectin, leptin), inflammatory markers (TNF, high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), plasminogen activator inhibitor (PAI-1)), fibrosis markers (N-terminal collagen type III propeptide (Pro-C3), enhanced liver fibrosis (ELF) test), lipid toxicity markers, quality of life endpoints, and pharmacokinetic (PK) endpoints. Based on the treatment effects observed in prior studies of NAFLD, the study is adequately powered to detect significant differences in change in hepatic fat fraction by MRI-PDFF compared to baseline in subjects with ALT-801 compared to subjects receiving placebo SC injections at a significance level of 0.05 (2-sided). All randomized subjects who received at least one dose of study drug (safety analysis population) will be included in the safety analysis.

[0167] The safety objective is to evaluate the safety and tolerability of ALT-801 in subjects with NAFLD. Primary safety endpoints include adverse events (AEs), vital signs, double product (mean heart rate × mean systolic blood pressure), liver function tests, incidence of hyperglycemic and hypoglycemic adverse events, physical examination, injection site reactions, and immunogenicity. Secondary safety endpoints include change from baseline glycemic parameters including fasting serum glucose, CGM parameters (area under the glucose concentration-time profile, time in range, and hyperglycemia and hypoglycemia), and HbA1c. Continuous safety data will be summarized by dose level and treatment (active or placebo) using descriptive statistics (arithmetic mean, standard deviation [SD], median, minimum, and maximum). Categorical safety data will be summarized using frequency counts and percentages by dose level, treatment group, and day, when applicable. AEs will be coded using the most recent Medical Dictionary for Regulatory Activities (MedDRA) version. A listing of AE data by subject will be provided, including reporter term, preferred term, system organ class (SOC), treatment, severity, and relationship to study drug. The number of subjects experiencing treatment-emergent AEs (TEAEs) and the number of individual TEAEs and injection site reactions will be summarized by treatment group, SOC, and preferred term. TEAEs will also be summarized by severity and relationship to study drug. Clinical laboratory assessments, including liver function tests and fasting serum glucose, vital signs (including calculation of RPP), and ECG assessments will be summarized by treatment group, dose level, and protocol-specified collection time points. A summary of changes from baseline at each protocol-specified time point will also be provided by treatment group. Physical examination changes will also be listed for each subject. Concomitant medications will be listed by subject and coded using the latest version of the World Health Organization (WHO) Drug Dictionary. Medical history will be coded using the latest MedDRA version and provided by subject.

[0168] Pharmacodynamic (PD) objectives include evaluating hepatic fat fraction, anthropometric parameters (e.g., body weight, waist circumference, BMI), lipid metabolism (e.g., cholesterol (total cholesterol, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), apolipoprotein (Apo) A and B, lipoprotein (a), and triglycerides (TG)), metabolic markers (e.g., leptin, hemoglobin A1c (HbA1c), adiponectin), inflammatory markers (e.g., tumor necrosis factor (TNF), high-sensitivity C-reactive protein (hs-CRP), plasminogen activator inhibitor-1 (PAI-1), monocyte chemotactic protein-1 (MCP-1), interleukin-1 (IL-1), IL-2, and IL-1) in NASH subjects. The objective of this study is to evaluate the effect of ALT-801 on PD parameters (e.g., leukin-6 (IL-6), and plasminogen activator inhibitor-1 (PAI-1)), fibrosis markers (e.g., N-terminal type III collagen propeptide (Pro-C3), enhanced liver fibrosis (ELF) test), and lipotoxicity markers. Changes in insulin sensitivity and secretion, anthropometric parameters, lipid metabolism, metabolic markers, lipotoxicity markers, and inflammatory markers will be enumerated and summarized by treatment group using descriptive statistics (number of cases (N), arithmetic mean, SD, median, minimum, maximum, geometric mean, and geometric coefficient of variation (CV%)). The effect of baseline BMI on PD parameters will be evaluated by covariate analysis.

[0169] Effects on quality of life (QoL) will also be monitored (change from baseline in Short Form-36 and Impact of Weight on Quality of Life-Lite Clinical Trials version (IWQoL-Lite for CT)). Changes from baseline in the two summary scores for physical health and mental health, the eight domain scores for SF-36, and the composite score of the IWQoL-Lite for CT will be enumerated and summarized by treatment group using descriptive statistics (N, arithmetic mean, SD, median, minimum, maximum, geometric mean, and geometric CV%). Inferential statistics applicable to continuous endpoints will be applied as described above.

[0170] Pharmacokinetic (PK) objectives are to assess ALT-801 and metformin concentration change from baseline. Individual ALT-801 and metformin concentration data will be listed and summarized by treatment group and time point with descriptive statistics (N, arithmetic mean, SD, CV%, median, minimum, and maximum). Individual and mean ± SD ALT-801 concentration-time profiles for each cohort will be presented graphically. Metformin concentration changes from baseline will be listed and summarized by treatment group and time point with descriptive statistics (N, arithmetic mean, SD, CV%, median, minimum, and maximum). Population PK models will be developed that allow prediction of individual subject ALT-801 plasma concentration-time curves and associated PK parameters. Covariates including sex, age, weight, BMI, and concomitant medications will be examined wherever possible, and exposure-response relationships will be examined for efficacy and safety endpoints wherever possible.

[0171] The results of this study demonstrate that ALT-801 administered by subcutaneous (SC) injection once weekly for up to 12 doses is safe and tolerable, with positive PD, quality of life, and PK effects, as well as glucose control, in subjects with NASH.

[0172] Example 8 Reduction of Liver Fat by Treatment with ALT-801 This example describes a study evaluating the effect of ALT-801 on liver fat fraction in human subjects. Subjects who meet the inclusion criteria and do not meet the exclusion criteria are randomized 1:1:1:1 to one of the following treatment groups: 1) ALT-801, 1.2 mg, SC, once weekly for 12 weeks; 2) ALT-801, 1.8 mg, SC, once weekly for 12 weeks; 3) ALT-801, 0.6 mg, SC in week 1, 1.2 mg, SC in week 2, 1.8 mg, SC, once weekly for 2 weeks (weeks 3 and 4), and 2.4 mg, SC, once weekly for weeks 5-12; or placebo (0.9% NaCl), subcutaneous (SC), once weekly for 12 weeks. Results are shown in Tables 19-23 (see also Tables 11 and 16-18 in the previous example) and Figures 6-13. Figures 6-8 show data for all measurable subjects, demonstrating liver fat reduction without significant safety issues, and Figures 9-10 show data for fatty liver subjects (subjects with fatty liver disease).

[0173] [Table 20]

[0174] [Table 21]

[0175] [Table 22]

[0176] [Table 23]

[0177] As noted above, robust changes in liver fat content measured by MRI-PDFF (mean relative change >90%) in subjects with MRI-PDFF >5% at baseline after 6 weeks of treatment with 1.8mg and 2.4mg ALT-801. Mean weight loss at week 6 was 1.8%, 5.4%, and 4.7% with 1.2mg, 1.8mg, and 2.4mg ALT-801, respectively, with a mean weight gain of 0.9% with placebo. Results of this study show that ALT-801 reduced liver fat in subjects, including those with steatosis (fatty liver disease). The PK profile confirmed that weekly dosing was appropriate. Blood pressure and serum lipid levels also improved in all groups. Glucose homeostasis was maintained. Ketogenesis, an indicator of increased fat burning (the expected glucagon effect), also improved.

[0178] Other advantages of the reagent and the method of using the same are also provided herein, as will be appreciated by those skilled in the art. Although certain embodiments have been described in terms of preferred embodiments, it will be appreciated that variations and modifications will occur to those skilled in the art. Therefore, it is intended that the appended claims cover all such equivalent variations that fall within the scope of the following claims.

Claims

1. 13. Use of a pharmaceutical dosage formulation comprising SEQ ID NO:1 in the manufacture of a medicament for lowering blood glucose, lowering body weight, and / or reducing liver fat in a human, wherein the medicament is configured to deliver a therapeutically effective amount of the pharmaceutical dosage formulation once a week.

2. The pharmaceutical composition comprises: a) induce total body weight loss, and / or b) induce hepatic fat loss, and / or c) The use according to claim 1, which induces weight loss in an obese human sufficient to bring said human's body weight back into the normal weight range of a lean, normal human.

3. The use described in claim 1 or 2, wherein the medicament is for the treatment of obesity.

4. The use described in claim 1 or 2, wherein the medicament is for the treatment of glycemic control.

5. The use according to any one of claims 1 to 4, wherein the medicament is a first-line treatment for glycemic control, obesity, NAFLD, NASH, and / or steatosis.

6. The use described in any one of claims 1 to 5, wherein the medicine is a supportive treatment involving diet and / or exercise.

7. The use described in any one of claims 1 to 6, wherein the human has type 2 diabetes, and optionally, the human also exhibits established cardiovascular disease.

8. The use of any one of claims 1 to 7, wherein the medicament is delivered about once weekly for about two weeks to about eight weeks, or more.

9. The use described in any one of claims 1 to 8, wherein the medicament is configured to be delivered on about days 1, 8, 15, 22, 29, and 36.

10. The use of any one of claims 1 to 9, wherein the medicament is configured to be delivered as a single dose for lowering blood glucose about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days or about 7 days after delivery.

11. The use of any one of claims 1 to 10, wherein the medicament is configured to deliver about 0.5 to about 10 mg of SEQ ID NO:1 per week, optionally about 1 to about 7 mg per week, about 1 to about 5 mg per week, about 1 to about 2 mg per week, about 1.2 mg per week, or about 1.8 mg per week.

12. The use of any one of claims 1 to 11, wherein the medicament is configured to be delivered about once a week or once every two weeks, optionally for at least a month, and optionally each dose containing approximately the same amount of SEQ ID NO:

1.

13. The use of any one of claims 1 to 12, wherein the medicament is configured to be delivered as a first dose weekly for one or more weeks and to be delivered as a second, higher dose weekly for one or more weeks.

14. The use of any one of claims 1 to 13, wherein delivery of the pharmaceutical dosage formulation exhibits a C max of about 400 to about 1300 ng / ml, a T max of about 10 to about 36 hours, and / or an AUC 0-48 of about 15,000 to 45,000 h*ng / mL.

15. The use of any one of claims 1 to 14, wherein the weight loss is at least 5%, at least 10%, or from about 1% to about 20%, or from about 5% to about 10% (w / w).

16. The use of any one of claims 1 to 15, wherein the medicament induces weight loss in an obese human sufficient to return the body weight of the human to the normal weight range of a lean, normal human.

17. The use of any one of claims 1 to 16, wherein the medicament is configured for subcutaneous delivery.

18. The use of any one of claims 1 to 17, wherein the pharmaceutical dosage formulation is an aqueous formulation comprising one or more of polysorbate 20, arginine, or mannitol.

19. The use of any one of claims 1 to 18, wherein the pharmaceutical dosage formulation comprises about 0.025-0.075% (w / w) polysorbate 20, about 0.2-0.5% (w / w) arginine, about 3-6% (w / w) mannitol in deionized water, pH 7.7±0.1, optionally about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, about 4.260% (w / w) mannitol in deionized water, pH 7.7±0.

1.

20. The use of any one of claims 1 to 19, wherein a pharmaceutical comprising about 1.8 mg of SEQ ID NO:1 is configured to be delivered once weekly for at least six weeks, and induces at least about 3-5% total body weight loss, optionally greater than 5% total body weight loss.

21. The use described in claim 20, wherein the net change in total body weight loss compared to placebo is at least about 6%, optionally about 6.3%.

22. The use of any one of claims 1 to 21, wherein a pharmaceutical comprising about 1.2 mg of SEQ ID NO:1 is configured to be delivered once weekly for at least six weeks, inducing at least about 2% total body weight loss, optionally about 1.8% total body weight loss.

23. The use described in claim 22, wherein the net change in total body weight loss compared to placebo is at least about 3%, optionally, about 2.7%.

24. Use of a pharmaceutical dosage formulation comprising SEQ ID NO:1 in the preparation of a medicament for chronic weight management in a human by inducing weight loss in the human having a body mass index (BMI kg / m2) of at least 25, wherein the medicament is configured to deliver a therapeutically effective amount of the pharmaceutical dosage formulation once a week, and wherein the human's body weight is reduced by at least 5% from baseline at week 12.

25. The use of claim 24, wherein the human's body weight is reduced by at least 6% from baseline at week 12, at least 7% from baseline at week 12, at least 8% from baseline at week 12, at least 9% from baseline at week 12, or at least 10% from baseline at week 12.

26. The use of claim 24, wherein the therapeutically effective amount of the pharmaceutical dosage formulation containing sequence ID no. 1 once a week is approximately 1.8 mg of sequence ID no.

1.

27. ​​The use described in claim 24, wherein the medicament is an adjunctive treatment involving increased physical activity and / or a reduced-calorie diet.

28. The use of claim 24, wherein the human has a BMI of at least 30 kg / m 2 .

29. The use described in claim 24, wherein the human is not diabetic at week 0.

30. The use of claim 24, wherein the medicament is configured to be delivered subcutaneously.

31. The use of claim 24, wherein the medicament is configured to be delivered once weekly for at least six weeks and induces a total body weight loss of at least about 3%.

32. The method of any one of claims 1 to 31, wherein the medicament reduces liver fat.

33. Use of a pharmaceutical dosage formulation comprising SEQ ID NO:1 in the preparation of a medicament for reducing body weight in a human, wherein the medicament is configured to deliver a therapeutically effective amount of the pharmaceutical dosage formulation once weekly for at least 12 weeks.

34. The use of claim 33, wherein the medicament induces at least 5% weight loss from baseline at week 12.

35. The use of claim 33, wherein the medicament induces liver fat reduction.

36. The use of claim 33, wherein the medicament lowers blood glucose.

37. The use described in claim 33, wherein the medicine is a supportive treatment involving diet and / or exercise.

38. The use described in claim 33, wherein the medicament is configured to be delivered on about days 1, 8, 15, 22, 29, and 36.

39. The use of claim 33, wherein the medicament is configured to be delivered subcutaneously.

40. The use of claim 33, wherein the pharmaceutical dosage formulation is an aqueous formulation comprising one or more of polysorbate 20, arginine, or mannitol.

41. The use of claim 33, wherein the pharmaceutical dosage formulation comprises about 0.025-0.075% (w / w) polysorbate 20, about 0.2-0.5% (w / w) arginine, about 3-6% (w / w) mannitol in deionized water, pH 7.7±0.1, optionally about 0.050% (w / w) polysorbate 20, about 0.348% (w / w) arginine, about 4.260% (w / w) mannitol in deionized water, pH 7.7±0.

1.

42. Use of a pharmaceutical dosage formulation comprising SEQ ID NO:1 in preparing a medicament for reducing the body weight of a human having a body mass index (BMI kg / m2) of at least 25, wherein the medicament is configured to deliver a therapeutically effective amount of the pharmaceutical dosage formulation once a week, and wherein the human's body weight is reduced by at least 5% from baseline at week 12.